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ABSTRACT

The development of an effective therapy for Duchenne Muscular Dystrophy
(DMD) is one of the primary goals of all DMD/Becker Muscular Dystrophy (BMD)
research. Golden Retriever Muscular Dystrophy (GRMD), an animal model of
DMD is a fatal degenerative myopathy. Unlike the mdx model, the GRMD dog
more accurately reflects the phenotype shown by human DMG patients, making
the model better suited for the investigation and assessment of potential
therapeutic approaches. The GRMD mutation, a base change from A to G in the
3' splice acceptor site of intron 6, results in exon 7 skipping which disrupts the
translational reading frame. As a result, affected dogs have drastically reduced
levels of dystrophin and its mRNA transcript.

Recently, genetic therapy with antisense oligonucleotides (AOs) has attracted
special interest as a novel therapeutic approach for DMD. AOs may be introduced
into myotubes to redirect the splicing of GRMD dystrophin pre-mRNA to restore
the reading frame. Ideally, this would increase the quantity of functional dystrophin
in affected DMD tissues to levels of therapeutic value.

The objective of this project was to identify intronic sequences from the canine
dystrophin gene in the region of the mutation to allow the design AOs to be trialed
as a therapy for GRMD. lntronic sequences that needed to be identified for the
design of AOs were at the boundaries of intron 5/ exon 6, exon 6/ intron 7, exon 8/
intron 8 and intron 8/ exon 9. It was hoped that the application of the appropriate
AOs would induce the processing/splicing of the dystrophin gene to exclude
exons 6 and 8 (exon 7 is omitted due to the GRMD mutation) to restore the
reading frame.

To detennine these intronic sequences, several intronic sequencing strategies were
attempted. These included long range PCR amplification, inverse PCR, PC R

IV

screening of a plagemid GR library, construction of a GR cosmid library for
hybridization screening and PCR screening of a phage canine genomic library.

This project determined the intronic boundaries of exon6/intron 6, intron 7/exon 8,
exon 8(1ntron 8 and intron 8/exon9.

Successful methods that identified intronko

sequences included long-range PCR amplification and ihe PCR screening of both
the phagemid and phage genomic DNA libraries. As it eventuated, this thesis also
reported the first attempt at AO-induced GR dystrophin ex on skipping in a G R
primary myoblast tissue culture.

;:
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CHAPTER 1.0

1.1

INTRODUCTION

Duchenne and Becker Muscular Dystrophy

The identilication of the human dyslrophin gene {Koenig et al., 1987) and its gene
product, dystrophin (Hoffman et al., 1987) was a giant leap in our understanding of
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy {BMD).

DMD is the most common human X-linked recessive muscular disease, with a world
wide incidence of 1 in 3500 live male births (Anderson & Kunkel, 1992).

DMD is

characterised by progressive muscle wasting and weakness of the skeletal muscles.
Affected boys clinically present between the ages of 3 to 5 years wtlh muscle
weakness and experiencing difficulty in rising from the floor. This is followed by
wheelchair confinement by or before 12 years of age. Death occurs from respiratory
or cardiac failure in the early to late 20s (Kakulas, 1997; Matsuo, 1996).

BMD is a milder allelic version of DMD (Becker & Keiner, 1955; Monaco et a/., 1988).
Although clinically similar to DMD in distribution of proximal limb weakness, B MD' s
onset and progression is variable and generally less severe (Anderson & Kunkel,
1992). Some GMD patients require a wheelchair from 16 years of age, other BMD
patients remain ambulatory into their third or fourth decade and may live full and
minimally restricted lives. One BMD patient with a deletion of exons 3 to 10 was not
diagnosed until the age ol62 years (Anderson & Kunkel, 1992; Malhotra et al., 1988).

1.2

The Dystrophin Gene and Protein

The dystrophin gene is comprised of 79 exons separated by introns of up to 200 kb
spread over approximately 2.5 megabases (Mb) and encodes the major muscle

specific isoform, a 14-kb mANA which is transla',ed into a dystrophin protein, consisting
of 3,685 amino acids (427 kDa) (Anderson & Kunkel, 1992; Roberts et al., 1993).
Immunocytochemistry studies revealed that dystrophin is a large cytoskeletal protein
expressed predominantly

n

skeletal muscle, where rt is located just beneath the

sarcolemma (Koenig et al., 1988; Watkins et al., 1988; Zubrzycka-Gaarn et al., 1988).

lmmunoblotting with domain specific antibodies, suggests that dystrophin is divided
into four distinct structural domains (Ahn & Kunkel, 1993). These are: the actin binding
domain (amino N tenninus); the internal region of dystrophin consisting of 24
homologous repeats, which, by analogy to p-spectrin, fonn a rod region; a cysteine
OCh domain and a carboxyl (C)-terminal domain. The C-terminus is the only region
which does not show sequence similarity to other proteins, suggesting that rt has
dystrophin-specific function (Koenig et al., 1988).

The C-tenninus is believed to

mediate the anchoring of dystrophin to the sarcolemma via a dystrophin-associated
complex of proteins and glycoproteins (Campbell & Kahl, 1989; Carpenter et al.,
1990).

While the specific function of dystrophin is yet to be elucidated, Samitt and Bonilla
( 1990) postulate that dystrophin is involved in the connection between the
extracellular matrix and the cytoskeleton, which provides strength and flexibility to
muscle fibres during contraction and relaxation. Other roles have been postulated,
including: an involvement in excrtation and contraction coupling (Harris et al., 1992); and
regulation of Ca '• movement (Turner et al., 1988; Harris et al., 1992). In addition,
dystrophin has recently been shown to anchor the free radical enzyme, nNOS
(neuronal nitric oxide synthase). Loss of nNOS localisation in DMD is believed to lead
to necrosis and free radical injury (Disatnik et al., 1998).

2

Western blot analysis of muscle biopsies from patients with DMD indicated that
dystrophin was generally either absent or present in undetectable quantities.
Dystrophin of altered size and/or abundance was detected in BMD muscle (Hoffman
et at., 1987, 1988; Beggs et at., 1991). Thus, the presence of partially functional
and/or reduced levels of dystrophin was sufficient to ameliorate the DMD phenotype
leading to the milder presentation seen in BMD (Beggs et at., 1991).

It may,

therefore, be possible to reduce the severity of DMD to that of BMD, if DMD patients
can be induced to produce some functional Becker-like dystrophin (Wilton et at.,
1999).

DMD and BMD have been shown to be caused by mutations in the dystrophin gene
located at Xp21.2 (Hoffman et at., 1987). Approximately 65% of DMD and BMD
patients have readily detectable intragenic deletions of one or more exons from the
dystrophin gene (Koenig et at., 1987; Forrest et at., 1988), while approximately 6%
have duplications of single or multiple exons (Monaco et at., 1987; Hu et at., 1990;
Galvagni, et al., 1994).

The remaining cases are minor or subtle DNA changes,

typically nonsense or spliee-site mutations (Hoffman & Kunkel, 1989; Den Dunnen,
1~87). The majority of the deletions are not randomly distributed throughout the gene
but clustered in hot spots where the introns are particularly large, and including
neighbouring exons. For example, in the large intron 7 and in the extremely large
intron between exons 44 and 45 (see review Kakulus, 1997; Nobile et al., 1997).

1.3

Dystrophin Mutations and Disease Severity

,,

,',1

From early analysis of these partial deletions,

nwas observed

that the size or location

of the gene mutation did not appear to correlate with the clinical severity of the patient's
disease (e.g. DMD versus BMD).

To explain these observations at the molecular

level, Monaco et at. (1988) proposed the reading frame hypothesis.

If,'

·''

",,

3

This

hypothesised that the severity of the disease was directly corrslated with the effect of
the genetic lesions on the open reading frame (OAF) in the dystrophin mANA
transcript.

It was proposed that intragenic deletions harboured by severe DMD patients would
bring exons together that, when spliced, resulted in a reading frame shift in the mANA
and premature tenmination of translation. The stop codon generated by the frameshift
would lead to the production of truncated dystrophin molecules downstream of the
mutation and would lack a carboxyl tenminus. This protein is presumed to be nonfunctional and rapidly degraded.

Conversely, deletions or duplications that brought together exons that maintained the
reading frame, resulted in the less severe BMD phenotype. It was presumed that the
synthesis of shorter or larger molecular weight protein molecules were semi-functional.

Subsequent analysis of lymphocytes from many hundreds of DMD and BMD
patients has proved that Monaco's "frame shift theory" was correct in over 90% of the
cases studied. This is now accepted as the explanation for the lack of dystrophin h
most DMD patients (Koenig et al., 1989; Den Dunnen et al., 1989). There are some
exceptions to the frame shift rule involving patients with a frame shift deletion of exons
3-7 who produce tow levels of dystrophin resulting in variable phenotypes, DMD,

BMD or intenmediate (Malhotra et al., 1988; Koenig et al., 1989; Chelly et al., 1990;
Gangopadhyay et al., 1992; Winnard et al., 1993).

Arahata et al. (1991) used a new monoclonal antibody directed specifically against the
C-tenminal portion of the dystrophin molecule and confinmed that all BMD patients
have dystrophin gene products which include the C-tenminal domain. In contrast, the
C-tenminal was absent in most patients whh DMD. This study not only substantiated

4

the validity of the reading frame hypothesis at the protein level but also emphasized
the critical importance of the C-terminal domain.

The resulting loss of only the C-

terminus is sufficient to destabilize the entire dystrophin protein and prevent proper
subcellular localization and function. However, a severe DMD patient with an intact Cterminus was identified by Prior et al. (1993).

This patient was shown to have a

missense mutation in exon 3 which substituted arginine for Leucine at position 54 in the
actin binding domain. This missense mutation did not disrupt the reading frame but
resulted i1 decreased production of correctly localised dystrophin protein to
approximately 20% of normal levels of dystrophin. Thus, this study showed that the
actin binding domain and the C-terminus are necessary for protein stability and
essential for proper dystrophin function.

1.4

Animal Models of DMD

Animal models have contributed significantly to the investigation and understanding of
a number of biological and pathological processes. They enable both basic research
and dnical tlials to be undertaken (Cooper, 1989). For ethical reasons, therapeutic
tlials cannot be performed on humans until a careful assessment of each therapy in a
suitable animal model has been conducted (Kornegay, 1992).

The potential

advantages of animal models for Duchenne-type muscular dystrophy has lead to the
investigation of several models (Cooper, 1989).

Defects in the dystrophin gene

resulting in animal DMD homologues have been reported in the mouse (Bullfield et al.,
1984), dog (Cooper et al., 1988c) and cat (Carpenter et al., 1990).

Of the three animal species i1 which Duchenne-type muscular dystrophy has been
identified, only the mdx mouse and the GR dog are available for study (Valentine et
al., 1992).

Despite offering convenience and economy, the mdx mouse model

shows little clnical disease, atlaining a normal lifespan (Cooper, 1993).
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Recently,

Partridge et al. (personal communication) found that stress and exercise exacerbated
the problem leading to cardiomyopathy. This phenomenon has not been reported
humans.

n

Unlike the mdx model, the GRMD dog more accurately reflects the

phenotype shown by the human DMD patients, making the model better suited for
the investigation and assessment of potential therapeutic approaches.

In practical

terms, the GR dog best serves as an intermediary between basic research on the

mdxmouse and the eventual application to human subjects (Partridge, 1991b).

1.5

GRMD as an Animal Model for DMD

A spontaneous GR degenerative myopathy, with clinical and pathologic characteristics
bearing close resemblance to DMD, was recognised by a number of investigators
(Meier, 1958; de l.anhunta, 1977; Cardinet, 1979; Valentine et al, 1986; Kornegay,
1988).

A similar myopathy had been recorded in many dog breeds including Irish Terriers
(Wentink et al., 1972), Samoyeds (Presthus & Nordostoga, 1989), Rottweilers and
Dalmatians (Cooper, 1993), Belgian Shepherds (Van Ham et al., 1995) and German
short haired pointer (Schatzberg et al., 1999).

However, the DMD·Iike syndrome

oocuning in the G R is similar to that in man and ij is also the most fully characterised
(Kornegay, 1992; Cooper, 1993).

Colonies of GRMD dogs have been successfully established in North America using
one of the dogs originally studied by Kornegay (1988).

Additional colonies have

been established in France and in Perth, Western Australia.

Apart from a severe neonatal form where death results in the first few days of life,
overt dnical signs of GRMD first become apparent al approximately 6 to 8 weeks.
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Before 8 weeks, some affected pups can be tentatively identified from poor weight
gain, sucking problems and a tendency to be lethargic (Cooper, 1989; Howell et al.,
1997).

Clinical signs include gross muscle weakness, an abnormal stiff-limbed, short strided,
shuffling gait (with characteristic bunny hopping of the hind limbs) and limited jaw
opening leading to difficulty in eating (Cooper, 1989; Nonaka, 1998). Serum levels of
creatine kinase (CK) are consistently and often dramatically elevated in affected dogs
(up to 300 :imes normal). This can be used to identify affected pups within the first
few days of life (Cooper, 1992; Cooper, 1993; Valentine P' al., 1992). However
normal pups can have elevated levels of CK from stress of birth. In advanced stages
there is a gradual decrease in serum CK level but

tt is always sustained above normal

levels (Valentine, et al., 1992).

Clinically, the disease onset is earlier and progresses more rapidly in the GR dogs
than in man. Again, in contrast to DMD, this rapid early decline is followed by a phase
of relative clinical stability, at about 6 months of age, before succumbing to cardiac and
respiratory failure months, or years, after birth. Some dogs may survive up to 6 to 7
years (Howell et al., 1997; Nonaka, 1998).

Histological examination shows the disease to be characterised first by the presence
of numerous hypercontracted muscle fibres and then progresses to prominent fibre
necrosis with infiltration and phagocytosis by macrophages. Concurrent degeneration
with mineralisation and regeneration leads to eventual endomysia! and perimysial
fibrosis wnh fatly infikration and cardiomyopathy (Partridge, 1991a; Kornegay et at.;
1990; Valentine et al., 1990).
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Despite the same descendance from a single affected GR male, considerable
phenotypic variation in the severity of clinical signs and disease progression in affected
dogs is evident. This suggests that factors other than mutations in the dystrophin gene
may play a role in the manifestation of clinical disease.

It is important therefore that

research is conducted to elucidate these "factors" which may be relevant to an
understanding of the clinical heterogeneity reported in human DMD (Valentine et al.,
1988; Cooper et al., 1988a).

As all affected dogs were males bam to clinically nonnal parents, rt was proposed that
GR disease was X-linked (Cooper et al., 1988b). To address this question, breeding
trials were conducted in which an affected male GR was mated to unrelated GR female
dogs. Putative carrier females from the F1 generation were retained and bred back to
the

origin~!

sire. To test the supposed X-linked pattern of inheritance, two proven

carrier bitches were bred to unrelated normal male dogs, a beagle and a GR.

From

these breedings, three out of seven males were affected, while all nine females were
nomnal. The pattern was consistent with the inheritance of muscular dystrophy as a fully
penetrant X-linked recessive trart (Cooper,

1989).

Recent breeding trials by

Valentine et al. (1992) also obtained results consistent with an X-linked inheritance.

Previously, Selden et al. (1975) established that the nonnal canine X-chromosome
had a size, centromeric location and G-banding pattern that were virtually identical to
those of the normal X-chromosome in humans. The cytogenetic studies conducted by
Cooper et al. (1988b), analysed the Giemsa-banded (G-banded) karyotypes from
affected and non-affected dogs and found no obvious chromosomal abnomnalities, the
X-chromosome, in particular, being nomnal.
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1.6

GRMD Molecular Genetics

Given that genetic infonnation encoded on the X-chromosome is highly conserved

n

mammalian species, Ohno (1973) and Cooper et al. (1988c), investigated the
possibility that the dystrophin gene might also be defective on the X-chromosome of
affected dogs.

Southern blots of genomic DNA from affected dogs were probed with human DMD
eDNA

n order to detect

a deletion in the canine homologue at the Ouchenne locus.

While no evidence of deletion or other defects in the coding portion of the Duchenne
locus was found, informative restriction fragment length polymorphisms (RFLPs) were
identified. Preliminary linkage analysis using these RFLPs revealed that the mutation
responsible for the canine disease was located on the GR X-chromosome in a region
homologous to the region of the human X-chromosome canying the human OM 0
locus (Cooper et al., 1988c).

Northern blots of RNA prepared from canine skeletal muscle and hybridised with the
same DMD eDNA probes revealed a 13.6 kb transcript in normal dogs similar to that
found in humen (14 kb) and mouse muscle (12.5 kb). In contrast, affected dogs lacked
this mANA transcript and GRMD appeared to be a animal homologue of OM 0
(Cooper et al., 1988c).

To establish whether dystrophin was absent in affected dogs, Western blots of
skeletal muscle from nonnal and dystrophin dogs were carried out.

Antibodies to

dystrophin detected a dystrophin band (400 kDa) from normal dogs, indistinguishable
from dystrophin present in human and mouse muscle. No dystrophin was detected i1
muscle from the affected dogs (Cooper et al., 1988c).
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These results were supported by immunohistochemical studies which confirmed that
the normal sarcolemmal ~taining pattern was absent in both skeletal (Cooper et at.,
1990) and cardiac muscle (Valentine et at., 1989).

However, a later study conducted by Valentine et at. (1992) used a highly sensitive,
chemilluminscent technique to probe Western blots and detected a very faint
dystrophin band that corresponded to the dystrophin band in normal dogs. While the
origin of this dystrophin is not clear,
dystrophin may be the

resu~

nwas

proposed that these very low levels of

of revertant fibres which have also been observed i1

DMD and mdxmouse muscle (Hoffman et at., 1990).

Sharp et at. (1992) conducted molecular studies that analysed the canine dystrophin
gene in normal and affected dogs. Exon 1 (forward) and axon 11 (reverse) primers
detected a dystrophin transcript truncated by 120 nucleotides when eDNA from
affected dogs was used as a target for PCR amplification. As this axon was present
at the genomic level, it was assumed that there was a splice site mutation inducing the
skipping of this axon. This mANA processing error was subsequently shown to be
the result of a point mutation, a base change from A to G in the 3' splice accep!or site
of intron 6. The seventh exon is then skipped which disrupts the reading frame and
leads to th" premature termination of dystrophin translation wrthin exon 8 in affected
dogs. This is shown in Figure 1.1.

!0

Nonnal

GRMD

tioo6

J

lntron ~

&oo7 llntron 71 &oo8

Permature termination of
dystrophin translation

Splicing

Nonnal
GRMD

g t t t c a g G CCA GAC ... .
g t t t c(IDg G CCA GAC ... .

&oo7

lntron 6

Figure 1.1: Diagrammatic Representation of Genomic DNA from Normal
and GRMD dogs during Splicing with the 3' Splice Site Mutation of lntron 6
ah~wn

1. 7

In the pink box.

Theraplaa for DM D

Tha development of an effective therapy for DMD is one of the primary goals of all
OMD/BMD research. Following the discovery of the central importance of the mutated

dystrophin gene to DMD, myoblast transplantation, gene therapy and genetic
therapies were pursued. The objective of all of these therapeutic approaches was to

It

increase the quantity of functional dystrophin in affected DMD tissues to levels of
therapeutic value (Anderson & Kunkel, 1992).

1. 7.1 Myoblast Transplantation

During growth and development, multinucleated skeletal muscle fibres are formed by
the fusion of mononucleated precursor cells (mpc) (See review Morgan, 1994).
Experiments

w~h

mice revealed that implanted mpc can fuse wrth growing or

regenerating muscle fibres to form mosaic fibres in which myonuclei of both host and
donor origin share a common cytoplasm (Watt et al., 1982, 1984). Mpcs have been
isolated from muscle, enriched, expanded in numbers and genetically engineered wrth
retroviruses in vitro before being injected into muscle (Biau & Springer, 1995).
Recently Gussoni et al. (1999) have demonstated the partial restoration of dystrophin
expression i1

DMD

muscle by

the

intravenous injection of either nonnal

haematopoietic stem cells or a novel population of muscle-derived stem cells into
inadialed animals.

The results from these preliminary studies indicate that the transplantation of nonnal
mpc (with nonnal genetic constitution) could become incorporated into the myopathic
muscle fibres where they would grow and repair the muscle. Therefore, the gene
products derived from the nonnal donor myonuclei would compensate for products
whiclh are deficient or abnonnal within the myopathic host muscle fibre (Morgan & Watt,
1993).

Despite some considerable success in the mdx mouse, similar experiments on DMD
patients have been disappointing (Morgan, 1994, Karpati et al., 1993). While the

cinicaJ trials with DMD patients have reported no adverse effects from cell injections,
patients failed to show any significant improvement in muscle strength. The estimated

12

number of surviving donor cells able to express dystrophin was very low (-1%)
despite the delivery of millions of donor myoblasts (Gussoni ot al., 1997).

In addition, mpc implantation in humans have been shown to remain relatively localised
at the site of injection wtlh only limited migration to damaged sites. As a result, the
large number of injections of myoblasts necessary to treat all of the affected muscle
reduces the likelihood that this method of treatment for DMD will succeed in the near
future (Biau & Springer, 1995).

1. 7.2 Gene Therapy

The object of gene therapy involves reconstituting a biological function by introducing a
gene into somatic cells, which are genetically deficient in that gene product (Dickson &
Dunckley, 1993).

The large size of the dystrophin gene makes tl impossible to

tmnsfer tl in tls entirety to dystrophin deficient somatic cells. Instead, the main aim of
DMD gene therapy has been to supply dystrophin cDNAs. in particular the muscle
specmc isoform consisting of a partial or full length eDNA driven by an appropriate
promotor (Matsuo, 1996).

While somatic gene therapy has been recognised as a possible approach leading to
effective therapy for DMD, tl has only been in the last few years that rapid scientific
advances have been made with the development of novel plasmid and viml vectors
(Marshall & Leiden, 1998).

As skeletal myofibres have a relatively long ha~-life in

vivo, they provide a stable

platform in which to express recombinant genes (Marshall & Leiden, 1998). Several
gene tmnsfer approaches have been tried to tmnsduce skeletal myocytes

in vivo.

These approaches include intramuscular injection (JM) with a variety of vectors including

t3

naked plasmid DNA, liposome complexed

DNA, adenoviruses and adena-

associated viruses (Morgan, 1994; Marshall & Leiden, 1998).

Dystrophin eDNA has been introduced into skeletal muscle fibres of dystrophin
deficient mice (mdx) through direct injection in plasmid expression vectors (WoiH et al.,
1990) and by replication-defective recombinant adenovirus vectors (Advs) (Karpati &
Acsadi, 1993).

The introduced genes appear to protect transduced muscle fibres

from necrosis. By direct injection of dystrophin eDNA as plasmids, expression has
only been achieved in about 1-2% of the adult mdx muscle fibres adjacent to the site
of injection (Wolf et al., 1990). Greater efticiency has been reported for recombinant
adenovirus injection into young mdx muscle (Karpati & Acsadi, 1993).

Although DMD gene therapy by the introduction of dystrophin constructs via retroviral
or adenoviral vectors has been shown to be possible in the mdx mouse (Morgan,
1994), there is an urgent need for the use of thR GRMD dog in gene therapy trails.
The GRMD dog muscle bulk reflects the proportions and distributions seen in humans
muoh more so than the tiny muscles of the mdx mouse.

It is obviously a more

relevant animal model in which to trial potential DMD therapies before their use i1
humans (Dickson & Dunckley, 1993).

Howell et al. (1998a) have recently demonstrated human dystrophin expression i1
dog muscle following the direct injection of a plasmid containing a dystrophin minigene. In a further study Howell et al. (1998b) administered modified adenoviruses
which canied the dystrophin mini-gene. This was rapidly followed by expression of
human dystrophin i1 over 50% of the fibres.

This was a muoh greater degree of

expression than had been previously obtained wijh plasmids. Immunosuppression,
premitted dystrophin expression has been maintained for periods up to 60 days i1
mdx mice and GRMD dogs (Howell, personal communication, 1999).
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Host immune responses to foreign cells or to adenoviral vectors have been reported
(Gussoni et al., 1997). The problem of immune rejection poses serious limitations to
the success of skeletal muscle based gene therapy. Strategies to minimise potential
pathological consequences, particularly

o continual

re-injection of the vector is

necessary, need to be developed in animal models. Trials should be conducted

n

both immunocompetent and immunocompromised hosts (Morgan, 1994; Marshall &
Leiden, 1998).

The first human trials of muscle-directed gene therapy are planed in the near future.
The timing of these trials depends on the Food and Drug Administration (FDA)
response to Muscular Diseases Association (MDA) proposals to sponsor these trials
(Wahl, 1998). It must be emphasised, however, that even

osuccessful !herapy were

to be accomplished in skeletal muscle, the treatment of heart and brain for
cardiomyopathy and borderline mental retardation still remains an outstanding problem
(Karpati & Acasdi, 1993).

1. 7.3 Genetic Therapy

As the injection of dystrophin minigenes into muscle is approaching human trials,
alternative genetic therapy strategies for DMD treatment are under development.
These aim to retard progression of the dinical symptoms by converting DM D
phenotypes to BMD phenotypes (Matsuo, 1996). Recently, revertant fibres (Wilton
et al., 1997a,b) and the antisense oligonucleotide (AO) alteration of splicing patterns
have been investigated (Dominski & Kale, 1993; Dunkley et al., 1995; Wilton et al.,
1999).
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1.7.3.1

Revertant Fibres

Despite the absence of dystrophin as detected initially by Western blot analysis,
subsequent immunohistochemical detection with anti·dystrophin antibodies revealed
the presence of dystrophin·positive fibres and clusters in approximately 50% of
DMD patients (Nicholson et al., 1989). These findings were also confinned in mdx
mice (Miike et al., 1989; Miyatake et al., 1989, 1991; Hoffman et al., 1990).
Dystrophin·positive fibres and in-frame transcripts have also been detected

n the

GRMD muscle tissue indicating that this particular "reversion" phenomena might be
widespread across several species (Valentine et al., 1992; Wilton et al, 1997b).

Dystrophin·positive fibres in DMD patients, GRMD dogs and mdx mice are termed
"revertants" or "revertant fibres" and appear to result from a rare but natural
phenomena.

Revertant fibres represent less than 10% of the total muscle fibre

population (Sherali et al., 1993). Dystrophin-positive fibres have been shown to
express true dystrophin and do not cross react with other related peptides (Hoffman
et al., 1990). Utrophin or dystrophin related protein (DRP) (397 kDa), shares similarity
to the protein domains of dystrophin and therefore can react with some anti-dystrophin
antibodies (Pearce, 1993).

While precise aetiology of the revertant fibre dystrophin has yet to be determined
(Klein et al., 1992; Uchino et al., 1995), postulated mechanisms for dystrophin·
positive fibres include: (i) nonnal, developmentally regulated alternative splicing (ii)
low-level illegitimate splicing (iii) somatic reversions (iv) somatic suppression and (v)
somatic mosaicism (Hollman et al., 1990, Klein et al., 1992).

Evidence has accumulated indicating that the first two mechanisms are unlikely
(Hollman et al., 1990). There is now growing support for dystrophin positive fibres as
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true genetic revertants generated from a somatic reversion-mutation mechanism in the
dystrophin gene.

The primary disease causing mutation (nonsense/frameshift)

appears to be bypassed by a second site in-frame mutation which restores the
translational reading frame. This provides a template for functional Becker-like proteins
(Hoffman et al., 1990; Klein et al., 1992; Zhao et al., 1993).

Mdx mouse dystrophin-positive fibres increase in frequency with age and X-irradiation

treatment (Hoffman et al., 1990). This may suggest that these fibres persist longer
because they have a selective advantage over dystrophin-negative fibres (Uchino et
al., 1995; Wilton et al., 1997b).

Evidence by Fanin et al. (1995) have revealed no correlation between dystrophinpositive fibres and the clinical severity of DMD, suggesting that these dystrophinpositive fibres are unable to improve the clinical phenotype of DMD, primarily due to
their low abundance. However Nicholoson et al. (1993) has found some correlation
between low levels of dystrophin and delayed restriction to wheelchair for some OM D
patients.

Characterisation of dystrophin-positive fibres, has raised the possibility of "genetic
therapy" for DMD. The dystrophin-positive fibres could be exploited by increasing
their numbers to biologically significant levels in DMD patients (Wilton et al., 1997a).

1.7.3.2

Antisense Oligonucleotide (AO) Technology

Over the past few years antisense oligonucleotides (AOs) have attracted special
interest as a novel class of therapeutic agents for treatment of genetic disorders,
emerging as a powerful tool

n genetic therapy

with a large and growing number of

applications (Temsamani & Guinot, 1997; Lavrosky et al., 1997). AOs are short single
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stranded molecules of RNA or typically DNA that hybridize target DNA or RNA
molecules

n

a sequence specific manner (Dunckley et al, 1995).

AOs have

previously been used to down-regulate gene expression, and has been achieved by
blocking translation (Agrawal, 1992) or by targeting an mANA

for RNaseH

degradation (Ghosh & Cohen, 1992). AOs have also been used to target specific
regions of DNA to inhibit transcription by RNA polymerase II (Maher et al., 1991;
Hanvey et al., 1992) and used to alter RNA processing (Dominski & Kale, 1993).

Dominski and Kale (1993) conducted an experiment which used AOs to manipulate
splice site selection ;, human p-globin thalassemic pre-mANA. In fl11 0 thalassemia,
an A to G mutation at nucleotide 11 0 in the first intron of the human p-globin gene
creates an additional aberrant 3' splice site. In spite of the presence of a nonnal splice
site, the aberrant splice site is preferentially used by the splicing machinery resulting i1
an incorrectly spliced mANA that contains 19 nucleotides of intronic sequence. A 14
mer antisense 2'-0-methylribonucleotide was designed to bind to the aberrant splice
site in intron 1 of the pre-mANA. This type of modified AO was selected as the 2'-0methylation (in which the non-binding oxygen atom is replaced by a methyl group)
renders the molecule resistant to nucleases. Thus stable hybrids are formed and are
not degraded by RNase H which would destroy the hetero duplex and prevent This
AO effectively reversed the aberrant splice site and restored correct splicing in vitro.
The resutts of Domanski and Kale (1993) raised the possibility of a new therapeutic
approach for DMD if nonnal splice sites could be blocked.

Dunckley et al. (1995) has shown that AOs can be used to manipulate splice site
selection in mdx mouse dystrophin pre-mANA. The mdx mouse carries a nonsense
mutation at position 3185 in exon 23 of the dystrophin gene. This mutation inactivates
the dystrophin gene of the mdx mouse resulting in tennination of translation wnhin
exon 23. A 2'-0-methyl oligonucleotides complementary to the 3' splice site of
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dystrophin intron 22 was delivered to the nuclei of primary mdx myoblast cuHures.
Direct sequencing of RT-PCA products from these cells revealed the removal ol
exons 22 to 30, thus skipping the mutant exon 23 and creating a novel in-frame
dystrophin transcript.

In a parallel study by Wilton et al. (1999) mdx myoblast cuHures were incubated with
an antisense oligonucleotide directed to the 3' and 5' splice site of intron 22 and intron
23 respectively

n the

mdx pre-mANA. The 5' AO appeared to efficiently displace

factors normally involved in the removal of intron 23 so that exon 23 was also
removed during the splicing of the dystrophin pre-mANA. The identity of the shorter
transcript, was confirmed by direct sequencing as an inframe dystrophin transcript
skipping exon 23, that is exon 22 joined to exon 24. This is shown in Figure 1.2.

.,,
'
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Figure 1.2: Diagrammatic Overview of Induced Exon Skipping, by the
Wilton et al (1999) study, to remove the Nonsense Mutation from the mdx
Dystrophln Gene. (not drawn to scale)

Redirected splicing of pre-mANA induced by AOs has the potential to minimise the
consequences of the gene mutation tihat causes DMD by restoring the reading frame.
Although this new approach is unlikely to herald a complete cure, it could

sign~icantly

reduce the severity of this devastating disease. Of particular importance is tihat all
tissue spec~ic isoforms would be expressed under endogenous control
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1.8

Objectives of the Project

This project aims to provide the basic research necessary for the evaluation of A 0
technology as a method of reducing the severity of DMD in another model of this
disease. The project focuses on the GRMD model of muscular dystrophy.

The

mutation that causes this disease falls in a region that is a known "hot spot" for DMD
deletions and therefore is very significant to human genetic therapy.

The objective of this project is to identify intronic sequences from the canine dystrophin
gene in the region of the mutation to allow the design of antisense oligonucleotides to
be trialled as a therapy for GRMD.

lntronic sequences that need to be identified for the design of AOs are at the
boundaries of intron 5/ exon 6, exon 6/ intron 7, exon 8/ intron 8 and intron 8/ exon 9.
Once

characterized, the appropriate

AOs

will

be

applied

to

induce

the

processing/splicing of the dystrophin gene to "cut out" exons 6, 8 and 9 (exon 7 is
omitted due to the GRMD mutation). This is the minimum change required to restore
the reading frame. Ideally, the dystrophin molecule translated from this novel in-frame
dystrophin transcript will be functional (Figure 1.3). At present,

~

is not certain whether

these exons to be skipped encode significant amino acids necessary for the function
of dystrophin. However human BMD patients missing exons 2-11, 2-8 and 3-16
(Bushby et at., 1993) have mild to moderate phenotypes, suggesting that the
dystrophin produced by the skipping of exons 6 to 8 will be at least partially functional
in Golden Retriever.
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Figure 1.3 - Diagrammati c Representation of the Aims of this Project

1.9

Experimental Approach

Since only the intronic sequence at the intron 6/exon 7 junction of the G R is available
(Sharp et al., 1992), several intronic sequencing strategies will be attempted. If
selected introns are · small, then it should be possible to amplify across individual
introns by conventional or long range PCR and then undertake direct DNA
sequencing. In the event that the introns are too large for the DNA amplification, other
approaches to find and identify selected splice sites will be undertaken. These include
phagemid library construction, Cosmid genomic DNA library and Lambda (A.) genomic
DNA library screening.

,.

'
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CHAPTER 2.0

2.1

AMPLIFICATION OF CANINE DYSTROPHIN INTRONS

INTRODUCTION

PCR is an in vitro method for enzymatically synthesising millions of copies of defined
DNA sequences.

The reaction involves two synthetic oligonucleotide primers that

anneal to opposite strands that flank the target DNA sequence which is to be amplified
(Mullis et al., t994; Boehringer Mannheim, 1995).

Extension of the primers is catalysed by a thermostable DNA polymerase, derived
from thermophilic eubacteria like Thermus aquaticus.

This is known as Thermus

aquaticus DNA polymerase, frequently abbreviated to Taq DNA polymerase.

A

repetitive series of cycles involving template denaturation, primer annealing and primer
extension by Taq DNA polymerase, results in an exponential accumulation of a
specific DNA fragment.

With each cycle, theoretically !he amount of target DNA

doubles, therefors after n cycles there is a 2" increase in the amount of double·
stranded target DNA (Erlk:h, 1989; Mullis et al., 1994; Cummings, 1994; Boehringer
Mannheim, 1995).

Conventional PCR is capable of amplifying up to 3 kb from genomic DNA targets
(Cheng, 1995). The lack of a 3' to 5' exonuclease or proofreading activity is believed
to aooount for this limitation, due to the inability of Taq DNA polymerase to correct
nucleotide misincorporations and continue primer elongation (Barnes 1994).

As the intron sizes for the canine dystrophin gene are unknown, the 'conventional' PC R
approach may be unsuccessful ff the introns under investigation are larger than 3 kb.
To overcome this limitation of conventional PCR, a modification allowing for the
amplffication of long DNA fragments has been developed (Barnes, 1994; Cheng,

2.1

1995). One such long-range PCR system has been developed by GibcoBRL, the
ELONGASE' enzyme krt. This krt uses a combination of two thermostable DNA
polymerases, Taq DNA polymerase and a potent proofreading Pryrococcus so.
thermostable polymerase present at a reduced quantity.

The presence of a

proofreading enzyme serves to remove nucleotides misincorporated by Taq DNA
polymerase, driving the extension of the target strands to between 12 to 20 kb
(GibcoBRL, 1999a).

2.2

METHODS

2.2.1 Genomic DNA Extractions

To provide target for long range amplification of dystrophin introns, genomic DNA was
extracted from three normal GAs. These animals were members of the GR colony at
Murdoch University.

Thymic tissue samples from two normal male GR (Chip

numbers, 19C5 and 6800) and one normal female GR (Chip number 1263) were
acquired from frozen (-SO'C) archival storage.

Thymic tissue was used for the

genomic DNA extractions due to its ready availability and its high DNA content.

2.2.1.2

The DNA Isolation Kit for Cells and Tissues

The DNA Isolation Kft for Cells and Tissues

supplied by Roche Diagnostics,

Australia, was used to extmct genomic DNA. This product claims to permit the rapid,
large scale isolation of genomic DNA mnging in size from 50 to 150 kb, free of
contaminating RNA and proteins. All components of the kit were stored at 4°C.
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2.2.1.3

Genomic DNA Extraction Protocol

DNA extractions were performed using 150-250 mg of thymic tissue. Due to the high
DNA content ol this tissue. the volumes of each solution required for the extraction
were based on specifications provided by the manufacturer for a starting tissue
sample of 400 mg. Throughout the DNA extraction, the samples and solutions were
kept at room temperature unless otherwise stated.

The tissue was frozen in liquid nitrogen, homogenised with a mortar and pestle, and
resuspended in 5 ml of cellular lysis buffer in a sterile 30m! centrifuge tube. To this
mixture, 6.1
lysis buffer.

~I

of Proteinase K solution was added, followed by another 5 ml of cellular
The sample was gently inverted 2 to 3 times to ensure that the

Proteinase K solution was mixed into the suspension.

In the presence of the

Proteinase K, the DNA and RNA were released into the solution.

The sample was

then placed at 65°C for 1 hour. A 400 ~I aliquot of RNAase A solution was added to
remove the RNA from the sample. The sample was then placed at 37°C for 15
minutes.

4.2 ml of protein precipitation solution was added to the sample and gently mixed for
5 to 10 seconds. The sample was then placed on ice for 5 minutes followed by
centrifugation at 13 000 rpm at room temperature for 20 minutes to remove the protein
from the suspension.

Upon centrifugation a protein pellet (and cell debris) was

fonmed. The supernatant containing the DNA was carefully withdrawn using a wide
bore tip and transferred into a sterile 50 ml centrifuge tube.

0.7 volumes of isopropanol was added to precipitate the DNA. The tube was gently
inverted until the upper and lower phases mixed. The visible DNA "strands" were
removed from the isopropanol with a plastic tip and placed into a sterile tube
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containing cold 70% ethanol. The mixture was swirled until the DNA strands were
released into the 70% elhanol.

The sample was then centrifuged for 5 minutes at 13 000 rpm. The supernatant was
discarded and the DNA pellet was left to air dry for 10 minutes. The DNA pellet was
resuspended in 300 ~I of nuclease free water and placed at 4°C overnight to dissolve.

2.2.1.4

Spectrophotometry

Spectrophotometery of the purified genomic DNA was performed using a Beckman
DU 650 (UV) spectrophotometer.

Nucleic acids absorb UV light predominantly at

260 nm whereas proteins absorb UV light predominantly at 280 nm. By measuring
the samples optical density (OD) at these two wavelengths, the concentration and
relative purity of the DNA was calculated.

To ensure accurate and consistent results, the UV light on the spectrophotometer was
switched on at least 15 minutes prior to measuring.

The spectrophotometer was

calibrated against the same water used to dilute the samples. An OD 260 value of 1.0
was considered to be equivalent to 50 ~g/ml of DNA (Sambrook et al., 1989). The
concentration of DNA samples was calculated as follows:

Concentration of DNA (11g/ml) = OD260 x dilution factor x 50

Nucleic acid purity was determined by comparing the ratio between reading at 260 nm
and 280 nm. The purity of the DNA sample was measured for protein contaminants
from the ratio OD,..IOD280 • An OD2..,10D280 of 1.8 represents high quality, pure DNA.
Values less than these figures are indicative of protein ami1or phenol contamination.
To check the sample for possible RNA contamination, an aliquot of the extracted DNA
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was fractionated on an agarose gel.

Any RNA contamination would appear as a

smear towards the bottom of the lane.

2.2.1.5

Agarose Gel Electrophoresis

The agarose concentration used to make the gel was determined by the anticipated
sizes of DNA fragments to be fractionated. This shown in Table 2.1.

Table 2.1: Agarose Concentrations Required to Separate DNA of

Various Sizes

Linear DNA Size {kb)

Amount of Agarose (%) tn gel

{wiv)
0.5

510 60
6 to 0.4
4 to 0.2 <b
2 to 0.1kb

1.0

2.0

3.0

(Sambrook et al., 1989)

As the extracted genomic DNA products were expected to be in the 50 to 150kb
range, a 0.5% agarose gel was prepared by pouring a 1% agarose in TAE base,
allowing this to set and then overlaying wnh 3 to 5 mm of 0.5% agarose.

An

appropriate amount of agarose powder was weighed out and added to 1xTAE in a
bottle. With the lid on loosely, the solution was heated in a microwave oven until the
agarose had completely dissolved.

It was then stored in a dry oven at 65°C until

required.

The molten 1% agarose solution was poured onto a perspex casting tray (Biorad) to a
depth of 3 to 5 mm. The gel was left to set for 15 to 30 minutes at room temperature.
A well forming comb was placed approximately 1 em from one end ol the casting tray
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above the 1% agarose base. The 1% agarose gel was then overlayed with 2 mm to
4 mm of 0.5% agarose and allowed to set.

The gel was then placed into an electrophoresis tank (Biorad electrophoresis sub cell)
and sufficient 1xTAE buffer was added to just cover the surface of the gel to a depth
of 1 mm. The comb was removed. 5

~I

aliquots of each sample were mixed with 1 ~I

of 6x GLB loading buffer and loaded into the wells of the agarose gel. A 5 ~I aliquot
of a DNA molecular marker (50

ng/~1)

was also loaded into the wells on the far left and

right sides of the gel (Figure 2.1 ).

Electrophoresis of the samples was performed between

70-1 00

volts for

approximately 1 hour. After electrophoresis was complete, the gel was stained
ethidium bromide (0.5

~glml)

n

at room temperature with gentle agitation for 30 minutes.

After staining, the gel was visualised using a Fotodyne UV-transilluminator and black
and white images were recorded using the Kodak® Digital Science"' DC120camera.

2.2.2

Long Range Amplification

Long mnge PCR amplification of intronic targets was performed using Elongase
enzyme kit (GibcoBRL, 1999a) according to the recommendations for genomic
targets provided by the manufacturer.

The PCR included a 'hot start' and was

composed of two separate mixes. one containing the template, primers and
nucleotides (Mix 1, Table 2.2) and another that contained the buffer and Elongase
enzyme (Mix 2, Table 2.3). Both mixes were prepared on ice

n 0.2 ml thin

walled

tubes. Mix 1 was constructed individually for each intronic primer set. Primers used to
amplify across the introns are illustrated in Table 2.4.
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SPP- 1 digested with EcoRI
(G eneworks, Australia)

N
\0

.i

I

8500 bp
7350 bp
6100 bp
4840 bp
3590 bp
2810 bp
1950 bp
1860 bp
15 10 bp
1390 bp
1160 bp
980 bp
720 bp
480 bp
360 bp

Figure 2.1:

pUC19 digested with Hpa II
(Genewo rks , Australia)

501 bp
489 bp
404 bp
331 bp
242 bp
190 bp
147 bp
111 bp
110 bp
67 bp
34 bp
34 bp
26 bp

DMW- 100M
(Gen eworks, Australia)

113000bp
2000 bp
1000bp

DNA Molecular Weight Markers used in Agarose Gel Electrophoresis.
The markers were diluted in loading buffer to a final concentration of 50 ng/~J..I
befo re use.

Table 2.2: Components of Mix 1
Volume (ld)
2
2
2

Components of Mix 1
SmMdNTPmix
Forward Primer
Reverse Primer
Genomic DNA (752) 1)lQIJll
Sterile water
Total

Final Concentration
10011M
200nM
200nM
1~g

to 20 Jll
20

Table 2.3: Components of Mix 2
Components of Mix 2
SX Buffer A

Volume (ul)
5

SX Buffer B

5

Elongase Enzyme Mix

1

(1 unit (U)/ul)
Sterile water
Total

Final Concentration
60 mM Tris 804 (pH 9.1), 18 mM
(NH 4 ) 2 1.5 mM Mg 804

1u

to 30 J.LI
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Table 2.4: Primers used to Amplify Canine Dystrophin lntrons
Canine

Primer Set

Sequence 5' to 3'

lntron
5

CanDysSF
Can6R

GGAAATCA(Cff)AAACTGACTCTIGG
CTGTGACTATGGATAAGAGCATICA

6

Can6F

GTCAAAAATGTAATGAAAAATATCAT
TIGTGTGGCTGACTGCTGGC

CanDys7R
7

Can7F

Can80R
8
9
Positive
control

GAACATGCATICAACATTGCC
GATGGCCTTGGCAACATTICC

ConDys9R

CAACAAGTGAGCATTGAAGCGAT
CATAAGCAGCCTGTGTG(Aff)AGGCAT

OysEX9F
Can100R

CCTAAGCCTGGATTCAAGAG
AATCTCTCCTTGGGCTIGGAG

Can79F

CAATGTAGGAAGCCT

UTA 13843R

TAAAACGTAGCAATAAAGCTC

ConDysBF
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All reaction components of the PCR master mixes, with the exception of the DNA
template, were added

n a pre-PCR

room with micropipettes that had never been

exposed to PCR products. A negative control consisting of all components of the
reaction mix except the template was also prepared for each primer set in order to
check for possible reagent contamination.

The DNA template was added using aerosol-resistant tips (to minimise contamination)
to Mix 1. The reaction was overlayed with one drop of paraffin oil to prevent
evaporation and condensation during thermocycling. The MJ tube control facility
minicycler was used to monitor reaction temperatures. The individual Mix 1 tubes
were placed in the thermocycler. The reaction was incubated at 94°C for 30 seconds
after which the Mix 2 containing the Elongase was added, followed by 35 cycles of
denaturation at 94°C for 30 seconds, annealing of primers at 50'C for 30 seconds and
primer extension at 68°C for 10 minutes.

On completing the PCR, a 5

~I

aliquot of the products was electrophoresed on an

agarose gel and the remaining products were stored at -20'C until further use.

2.2.2.1

Gel Purification of Long Range PCR Products

The long range amplification PCR products were gel purified on a 1.5% low melt
agarose gel. 20 to 30 fll of the PCR product was mixed wrth 5 fll of loading 6x G LB
buffer and loaded into a wide well created by taping two comb teeth together. After
fractionation, the gel was stained with freshly prepared ethidium bromide and
visualised briefly by UV transillumination. The band of interest was excised from the
gel with a clean sterile scalpel blade as quickly as possible to minimise damage to the
DNA by UV light and then transferred into a 1.5 ml eppendorf tube.
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The QIAquick PCR purification kil (supplied by QIAGEN, Australia) was used to
purify gel fractionalised PCR products from contaminants such as primer dimers and
amplification primers, unincorporated nucleotides, and enzymes (Qiagen, 1997). All
solutions and spin columns were provided with the kil.

Purification was performed

according to the protocol provided by the manufacturer.

Five volumes of buffer PB was added to the excised DNA agarose band in the
1.5 ml eppendorf tube. The sample was then placed at 65'C to melt the agarose ( -1
minute). The sample was then applied to a QIAquick spin column placed il a 2 ml
collection tube. The sample was then centrifuged for 1 minute at 14 000 rpm and the
flow-through discarded.

The QIAquick column was placed back into the same

collection tube and the sample washed with 750

~I

of buffer PE which was

subsequently centrifuged for a further 1 minute. The flow-through was discarded and
the QIAquick column was centrifuged for an additional 1 minute at maximum speed to
remove any residual buffer PE. The QIAquick column was then placed into a sterile
1.5 ml eppendorf tube. The DNA was eluted by adding 30-50

~I

of nuclease free

water to the centre of the QIAquick column and centrifuging for 1 minute.

An aliquot of the purified DNA products sample was electrophoresed on an 2%
agarose gel to estimate the concentration and the integrity of the DNA for the purpose
of DNA sequencing.

2.2.2.2

DNA Sequencing

The ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit supplied
by Applied Biosystems is a modification of the Sanger dideoxy sequencing method
(Sanger et al., 1977).

Cycle sequencing is based on the ability of a DNA

polymerase to extend a primer, annealed to the sequencing template, until a chain
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terminating dideoxy nucleotide is incorporated. Each sequencing reaction includes the
four types of deoxyribonucleotide triphosphates (dNTPs: dATP, dCTP, dTIP an~
dGTP), four different dideoxyribonucleotide triphosphate (ddNTPs) each labelled with
a different fluororescent dye (ddATP-green, ddCTP-blue, ddTIP-red and ddGTPyellow), one primer, buffer, magnesium and a thermostable DNA polymerase. Chain
tennination occurs when a ddNTP is incorporated in to the DNA strand as the ddNTPs
lack the 3'-0H group necessary for chain extension. As the concentration of ddNTPs
is much lower than that of the dNTPs, the chain tennination occurs randomly at G, A,T
or C, depending on the respective dideoxy analogue i1 the reaction. The resulting
fragments, each w~h a common origin but a different tennination point, are separated
by electrophoresis allowing the nature of the fluorescence and hence the c:hai1
tenninating nucleotide to be identified. Data is recorded electronically and presented
as a chromatographic intensity profile with ATGC translation (Brown, 1994).

The Big Dye'" tenninator cycle sequencing reaction contained 4 ~I of the tenninator
premix, 1

f.il

primer ( -50ng) and the appropriate amount of DNA as template 1-5 ~I

made up to a final volume of 10 ~I with nuclease free water.

All reactions were placed into a MJ mini cycler w~h a Hot Bonnet (does not require
paraffin overlay) and amplified as follows: 94°C for 30 seconds, 50°C for 30 seconds
and 60'C for 4 minutes and 15 seconds. The cycle sequencing was conducted for 30
cycles and left at 4°C until purification.

On completion of the thennal cycling, [ was necessary to separate the sequencing
reaction products from excess nucleotides and primers from the sequencing reaction,
prior to the products being analysed on an ABI 373A DNA sequencer.
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Ten microlilres of nuclease free water, 50

~I

of 95% ethanol and 2

~I

of 3M sodium

acetate (pH 5.2) was added to the sample which was vortexed and left to stand at
room temperature tor 15 minutes. The precipitate was then centrifuged a1 14 000 rpm
for 30 minutes. The supernatant was removed with a pipelle and the remaining pellet
was washed with 250 ftl of 75% ethanol and centrifuged for 15 minutes. The ethanol
wash was removed and the sample air-dried for approximately 1 hour.
The SeqEd 675 DNA sequence editor was used to visulise text and chromatograms
of the sequence template. Chromatograms were also manually examined to confirm
the computer assigned calling of bases in the sequence.

2.3

RESULTS

2-3-1 Genomic DNA Extractions

The concentration and relative purity of the extracted DNA was assessed after
spectrophotometry and agarose gel electrophoresis.

The DNA extracted from the three GR samples ranged in concentration and purity.
There was no evidence of RNA contamination after agarose gel electrophoresis as
illustrated

n Figure

2.2 (p. 35).

Protein contamination was present in the DNA

extraction from dog 1263 sample, as indicated by an 00 2601280 nm ratio of less than
1.8 (Table 2.5). This sample was disregarded and not used in further applications.

34

Lanes

2

3

4

5

6

Figure 2.2 : Genomic DNA Extractions. Agarose gel electrophoresis of genomic
DNA extractions from three golden retriever thymic samples.
Extractions and
electrophoresis was performed as described in methods sections 2.2 .1.3 and
2.2.2.5. Lane 1: Lambda (A) Ladder one(- 100 kb). Lane 2: A Ladder two(- 50
kb). Lane 3: Sample 19C5. Lane 4: Sample 6800. Lane 5: Sample 1263. Lane
6: Undigested A.

Ta ble 2.5: Concentration and Purity of the Extracted Genomic DNA

Sample
(chip numbers)
19C5
6800
1263

OD2 601280

ratio

1 .8
1 .8
1 .6

Concentration

(~J.g/ml)

1088 .3
768.3
1562 .5

The genomic DNA samples were approximately of 50 kb or greater.

This was

determined by comparison to the undigested A cloning vector which is approximately

48.5 kb and to the two A ladders created through concatemerisation of the A vector .

.

'
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2.3.2 Long Range Amplification

Figure 2.3 shows the long range amplification of introns 5 to 9 by

Elongase

(GibcoBRL, 1999a). Only the amplification with the intron 8 and intron 9 primer sets
yielded strong product bands that were obseNed at approximately 1.4 kb and 1 .1 kb
respectively (Figure 2.3). In contrast, the amplification with primer sets for introns 5, 7
and the positive control showed non-specific smearing, while multiple bands were
observed for intron 6. All reaction negative controls were free from contamination,
except the intron 6 negative control in which a faint but distinctive band was observed
at~

2.0 kb.

Lane

1

2 3

4 5

6

7 8

9 10 11 12 13 14

Figure 2.3: Long Range Amplification of Canine Dystrophin lntrons. Lane 1:
SPP-1 molecular weight marker. Lane 2: lntron 5. Lane 3: lntron 5 negative control.
Lane 4: lntron 6. Lane 5: lntron 6 negative control. Lane 6: lntron 7. Lane 7: lntron
7 negative control. Lane 8: lntron 8. Lane 9: lntron 8 negative control. Lane 10:
lntron 9. Lane 11 : lntron 9 negative control. Lane 12: Exon 79-UTR. Lane 13:
Exon 79-UTR negative control. Lane 14: SPP-1 molecular weight marker .

.

'
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Forty microlitres of the inlron 8 and 9 PCR reaction were separated on a 1.5%
LMPAG.

The bands were excised and purified using Qiaquick purification system

(Qiagen, 1997). Five microlitres of the purified DNA was electrophoresed on a 1%
agarose gel at 100 V for 50 minules to estimate the concenlration of the PCR product
after purification. Discreet bands were observed at 1.4 kb and 1.1 kb for intron 8 and
9 respectively.

2.3.3 Sequencing

Two microlitres of the purified intron 8 and 9 products were used as templates in the
sequencing reactions. The original amplification primers were used to sequence intron
8 and 9 in both directions to establish the sequence of the 5' and 3' splice sites.
lntronic sequences were obtained for intron 8

n both

directions (Figure 2.4 and 2.5).

The sequencing of intron 9 revealed that this PCR product was in fact a PCR reaction
artefact. An 2'-0-methyl antisense oligonucleotide was designed at the 5' splice sile of
intron 8 to

indu~e

skipping of exon 8 and ordered through Geneworks, Australia

(Figure 2.4).

Further attempts were made to optimise the PCR for the amplification of introns 5, 6,
and 7. PCR strategies that were attempted included varying the amount of DNA to
decrease background smearing, increasing the annealing temperature to 55°C to
increase the specificity of the primers and lastly, increasing the extension times to 15
minutes. Temperatures could not be raised above 55°C as the GC content of the
primers was less than 50%. Despite these further attempts to optimize the PCR, no
specific PCR products were obtained.
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TCAAATGCACTATTCTCAACAG
(NCBI ACCESS ION: AF070485)
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Exon 8
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Figure 2.4:
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Chromatogram of the 5' Splice Site of lntron 8 obtained from Long Range
Amplification of Canine Dystrophin lntrons and below the AO Designed to Block
this Stite

A TCAC A GTCAGTCTAGC
(NCBI ACCESSION: AF070485)
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lntron 8

Figure 2.5:

if,

l\

Exon 9

Chromatogram of the 3' Splice Site of lntron 8 obtained
from Long Range Amplification of Canine Dystrophin
lntrons

I

~I

2.4

CONCLUSIONS

Both spectrophotometric and agarose electrophoresis analysis indicated that the
genomic DNA extracted using the DNA isolation kit tor cells and tissues (Roche
Diagnostics. Australia) was of sufficient quantity and quality to be suitable for long
range amplification and for further applications in this project.

Long range amplification of intron 8 from canine genomic DNA was successful n
amplifying a 1.4 kb PCR product.

Sequencing of this PCR product wijh both the 8 forward and 9 reverse primers
identified the 5' and 3' splice sites of intron 8.
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CHAPTER 3.0

3.1

PCR SCREENING OF A CANINE PHAGEMID LIBRARY

INTRODUCTION

The next experimental approach was to construct a canine (GR) genomic DNA
phagemid library. This was to be used to PCR screen the remaining dystrophin
intron/exon boundaries.

As conventional PCR can only amplify DNA targets less than 3 kb, the basic strategy
of this experiment was to construct a phagemid library in which the genomic DNA
inserts were less than 1.0 kb. Due to the small sizes of the DNA inserts, the library
was to be screened by conventional PCR using ex on specific primers and the M 13
primer sites flanking the multiple cloning site (MSC).

3.2

METHODS

3.2.1 The Plagemid Vector

Phagemid vectors are plasmids which have been artificially manipulated so as to
contain a small segment of filamentous phage genome such as M13, fd or ft.
Phagemids permit the successful cloning of inserts several kilobases fang. The
pBfuescript II SK' phagemid vector supplied by Stratagene was selected for the
construction of the canine phagemid library, because it was a suitable vector and

~

was

available in the laboratory. The pBiuescript It SK' phagernid vector is a 2961 bp
phagemid derived from pUC19 and contains a MCS of 657-759bp.
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3.2.2 Preparation of Vector DNA

15 fig of the pBfuescript fl SK' vector DNA was digested with 100 U of Sma1
(recognition sequence: CCC~GGG) in a total volume of 200 ~I (20 ~I of 1Ox
multicore buffer, 165 ~I water) for 2 hours at 37'C. Enzyme activity was terminated by
heat inactivation for 15 minutes at 65'C. The sample was then ethanol precipitated by
the addition of 2.5 volumes of 100% ethanol and 1/10 volume 0.3 M sodium acetate,
followed by centrifugation at 13 000 rpm for 10 minutes at 4'C. The supernatant was
removed and 100

~I

of 70% (w/v) ethanol was added.

The sample was again

centrifuged at 13 000 rpm for 10 minutes at 4'C. The ethanol wash was removed and
the DNA pellet left to air dry at room temperature for 15 minutes. The DNA pellet was
resuspended in 30

~I

of water to a final concentration of 0.5

~g/~1.

3.2.3 Preparation of Genomic DNA: Blunt End Digestion

Using the canine genomic DNA extracted from GR dog 6800 (Section 2.2.1 .. p. 24 ),
two complete digests of genomic DNA were constructed. One digest using Sma1, a
six-base cutter, with the other using Rsa1, a four-base cutter (recognition sequence:
GT ~AC).

3.2.3.1

Sma1 Complete Digestion of Genomic DNA

10 fl9 (1.0 llg/fll) of canine genomic DNA was digested with 80 U of Sma1 and
dephosphorylated w~h 0.8 fll of Shrimp Alkaline Phosphatase (SAP) (U/pl) in a final
volume of 200 fll at standard buffering conditions (20 111 of 10 X multicore buffer and
160 fll of wafer) for 2 hours at 37'C.

The sample was ethanol precipitated as
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described in Section 3.2.2 (p. 42). The DNA pellet was resuspended in 20 pi of
nuclease free water to a final concentration of 0.5 pg/pl.

3.2.3.2

Rsa1 Complete Digestion of Genomic DNA

10 pg (1.0 pg/pl) of canine genomic DNA was digested with 80 U of Rsa1 and
dephosphorylated with 0.8 pi of SAP (U/pl) to a final volume of 200 pi at standard
buffering conditions (20 pi of 10 X muHicore buffer and 160 pi of water) for 2 hours at
37°C. The sample was ethanol precipitated as in Section 3.2.2 (p. 42). The DNA
pellet was resuspended in 20 pi of nuclease free water to a final concentration of 0.5
pg/pl.

3.2.3.3

Agarose Get Electrophoresis

5!11 aliquots of complete digestions of both vector and insert DNA

were

electrophoresised on a 2% agarose gel, stained with ethidium bromide and
photographed for analysis.

3.2.4 Ligation of Phagemid Vector and Insert DNA

Ligation was performed using a 1:3 molar ratio of vector to insert DNA as per the
recommendations made by the Promega (1996), "Protocol and Application Guide"
(p. 45) for a 3.0 kb vector and a 0.5 kb insert. The ligation was constructed according
to the manufacturers directions (see, Table 3.1 ). Incubation was ovemight at 14'C.
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Table 3.1: Ligation Reaction

Component

Volume

Vector DNA (O.S~tg/~tl)
Insert DNA (O.S~tg/pl)
T4 DNA Ligase (GibcoBAL)
Ligase 1Ox Buffer
Nuclease Free Water
Total

(~I)

Final Concentration

3

500 ng
1500 ng

0.3

1 U (Weiss units)

5

1x

41

50

Three 10 1.!1 ligation controls were also constructed lor the vector DNA only and for
each of the digested insert DNA.

3.2.5 Screening by PCR Amp!ification

3.2.5.1

Primary Amplification

As only a few copies of the exons of interest existed in the phagemid library, an
asymmetric PCR approach was adopted for primary amplification. Components of
the primary amplification are outlined in Table 3.2. In this method, the conventional
PCR was set up but using only the exonic primer for the first 40 cycles of amplification.
On completion of thennocycling, the M13 primer was added and thennocycling
conditions recommenced for a further 20 cycles. In this way the reaction was enriched
with linear fragments that contained only the exon of interest before the M13 primer
was added. Primers used for primary amplification are illustrated in Table 3.3.
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Table 3.2: Components of the Primary Amplification PCR

Component
Sterile water
5.2100
Primers (SOng/pi each)
Thermus thermus ( Tth) DNA
polymerase (S.SU/)JI)

Target DNA

Volume _()Ill
12.9
5

Final Concentration
1x PCR buller, 2mM MgCI~ +
1OOpM dNTP's

4 ng/111
0.05 U/pl

2
0.1
5

Total

25

Table 3.3: Primers used tor Primary Amplification

Canine Exon
6

Seauence 5' to 3'

8
9

Primer Direction
F
R
R
F

GTCAAAAATGTAATGAAAMTATCAT
CTATGACTATGGATGAGAGCATTCA
GATGGCCTTGGCAACATTTCC
CCTAAGCCTGGATTCAAGAG

M13F
M13R

F
R

CGCCAGGGTTTTCCCAGTCACGAC
AGCGGATTTCAATTTCACACAGGA

Thennal cycling was performed under the following conditions: 94°C for 2 minutes
followed by 39 cycles of 94°C for 30 seconds, SS'C for 1 minute and 72°C for 2
minutes. On completion of the thennocyling conditions the vector primer was added
and the thennocycling conditions recommended for a further 20 cycles.

The PC R

reaction products were then electrophoresed on a 2% agarose gel, stained with
ethidium bromide and photographed for analysis.

3.3.5.2

Secondary Amplification

Fragments generated from primary amplifications were isolated from other products

n

the sample through secondary amplification using a semi-nested PCR technique. The
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semi-nested approach involves using exonic primers internal to the exonic primers
used in the primary amplification. This acts to increase the specificity and sensitivity of
the amplification reaction.

The components of the semi-nested PCR reaction are

shown in Table 3.3. Primers used for semi-nested PCR are illustrated in Table 3.4.

Table 3.4: Components of Secondary PCR Reaction Mix

Comp_onent
Sterile water
5.150

Volume

j~l)

Final Concentration

34
10

1X PCA ReactiOn Buffer,
50 mM dNTP's and 1 mM

MgCI,
Primers (50ngtml)
T. th DNA polymerase (S.SU/)..11)
Target DNA
TOTAL

4

0.2

4 ng/)..11

0.11

U/~1

50

Thennal cycling was pertormed under the following conditions: 94°C for 2 minutes
followed by 39 cycles of 94'C for 30 seconds, 55°C for 1 minute and 72'C for 2
minutes.

Table 3.5: Primers used for Secondary Amplification

Canine Exon
Exon61R"
CanS A
DMD2a

3.3.5.3

Primer Direction
Nested A
Nested A
Nested F

Sequence 5' to 3'

CG(A/G)ACCCAGCTCAG(AIG)AGAATC
CATTAAGATGGACTTCTTATCTGG
CGATTCAAGAGCTATGCCTAC

Bandstab PCR

Bandstab PCR (Wilton et al., 1997c) was another technique used for secondary
amplification of PCR products.

The bandstab mixtures were prepared using the
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same reaction conditions as the sem1-nested secondary PCR (Section 3.3.5.2),
however template DNA was taken directly from a band in an agarose gel. After gel
fractionation and ethidium bromide staining of the PCR products, the gel was rinsed
briefly with distilled water. The band of interest was stabbed with a sterile yellow
pipette tip and the lip placed into the reaction mix for one minute. The contents of the
pipette tip were expelled into the PCR reaction. The reaction was overlayed with
paraffin oil before thermocycling. The cycling conditions are outlined in section 3.3.5.2.

3.2.6 DNA Sequencing

Products to be sequenced wgre purified us1ng the Qiaquick purification system as
previously described in Section 2.2.2.1. (p. 31 ). DNA Sequencing was conducted as
outlined in Section 2.2.2.2 (p. 32) using the nested exonic primers to generate the
product.

3.3

RESULTS

3.3.1 Digestion of Vector and Insert DNA

Figure 3.1 (p. 48) shows the digested products of the phagemid vector DNA and the
canine genomic DNA. The digestion of the vector was successful and observed as a
2.81 kb fragment. The Sma1 digest of the dog genomic DNA was not successful.

The genomic DNA appeared to have changed litlle in regard to size. In contrast. the
complete Rsa1 digestion was successful and observed as a smear of DNA
extending from - 3.5 kb to less then 300 bp.
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Lane

1 2

3

4

!5 6

Figure _3.1: Digestion of Phagemid Vector and Canine Genomic DNA. Lane 1:
SPP -1 molecular weight marker. Lane 2:

Sma1 digested canine genomic DNA.

Lane 3: Sma1 bluescript vector DNA. Lane 4: Rsa1 digested canine genomic DNA .
Lane 5: undigested A. Lane 6: Blank.

3.3.2 Ligation _?f Vector and Insert DNA

The ligation of the vector and insert DNA is shown in Figure 3.2 (p. 49) .

While

smeary, a distinct upward shift of DNA above the digested vector was observed for
the Rsa1 digested genomic DNA inserts and the phagemid vector, indicating that
ligation had taken place.

The Sma1 digest did not appear to have worked as

successfully. Out of the three controls only the Sma1 digested DNA was not detected
on the agarose gel suggesting the presence of an inhibitory substance contained with
the digested DNA sample .
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Lane

Figure 3.2 :

1

2

3

4

5

6

Ligation of Vector and Insert DNA.

Lane 1:

Ligation of Sma1

digested canine genomic DNA with the digested bluescript vector. Lane 2: Ligation of
Rsa1 digested canine genomic DNA with the digested bluescript vector.

Lane 3:

Ligation of digested bluescript vector. Lane 4: Ligation of Sma1 digested genomic
DNA. Lane 5: Ligation of Rsa1 digested canine genomic DNA. Lane 6: SPP- 1
molecular weight marker.

3 .3.3 PCR Screening

Figure 3.3 (p. 50) shows the primary amplification of exons 8 and 9. Two product
bands were observed at approximately 720 bp and 350 bp for the exon 8 and

49

M 13-120 forvvard primer combination.

For ex on 9, only one product band was

observed at -720 bp fo r the ex on 9F and the M 13 forward primer.

Lanes

Figure 3 .3:

1

2

3

4

5

6

Primary Amplification of the Canine Genomic DNA Phagemid

Library for Exons 8 and ex on 9. Lane 1: Ex on 8 reverse and M 13R. Lane 2:
Exon 8 reverse primer and M13F.

Lane 3:

Exon 9 forward and M13R.

Lane 4:

Ex on 9 forward and M 13F. Lane 5: Positive control; M 13 F and R. Lane 6: S P P- 1
molecular weight marker.

Secondary amplification of exon 8 using nested primers amplified both the small and
large PCR fragments (Figure 3.4, p. 51) . These fragments were separated through
gel purification on a 1.5% LMPAG (as described in Section 2.2 .2.1, p. 31 ).

The

sequencing of the only, small - 350 bp product obtained the intronic sequence for the
3' splice site of intron 7 as illustrated in Figure 3.5.
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Lane

1

2

3

Figure 3.4: Secondary Amplification of Primary Ampl ification Products from
Exon 8 and 9.

Lane 1: SPP-1 molecular weight marker. Lane 2:

Semi -nested

amplification of ex on 8 and M 13F. Lane 3: Semi -nested amplification of ex on 9 and
M13F.

Secondary amplification of exon 9 failed to produce any significant product.
optimisation by decreasing the annealing temperatures to 55

oc

Further

and 58°C failed to

produce any significant products.

Ampl ification of exon 6 (Figure 3.6) was conducted at 55°C as a result of the low G C
content of t,he exon 6 primers. Figure 3.6 shows the primary amplification of exon 6
from the phagemid library. A - 350 bp PCR product was produced for both the 6F
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ATGTTGCCACCACTTATATCCA
(NCBI ACCESSION : AF070485)
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3.4

CONCLUSIONS

The PCR screening of the canine GR genomic DNA phagemid library was successful

in amplifying a 350 bp PCR product using the exon 8 reverse and M13 forward
primers. Sequencing of this PCR product with the exon 8 reverse primer identified
the 3' splice site of intron 7.

CHAPTER 4.0

4.1

COSMID LIBRARY CONSTRUCTION

INTRODUCTION

A genomic libral)' contains the total sequences present in the genome ol an organism.
The larger the insert ol genomic DNA in each recombinant. the lower the number of
recombinants needed to completely represent the organisms genome (Strachan &
Read, 1996).

Cosmid vectors are synthetic hybrids possessing the desirable features of both
plasmid and bacteriophages and permit the cloning and propagation of large
fragments of fore'gn DNA (Strachan & Read, 1996). Cosmid vectors complete with
an in

vitro packaging system can clone genomic DNA in the 32·47 kb rang8 and are

therefore preferred for the construction of genomic libraries for screening

by

conventional hybridisation.

In this experiment, a GR genomic cosmid libra f)' was constructed, initially to identify the
inlronic sequences surrounding exon 6.

4.2

METHODS

4.2.1 The Cosmid Vector

The SuperCos 1 vector supplied by Stratagene was selected for application due to
its ability to accommodate genomic DNA fragments ranging in size from 30 to 42 kb.
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4.2.1.1

Preparation of Vector DNA

Isolation of SuperCos 1 cosmid vector DNA was based on Sambrook et al ( 1989)
protocol for preparation of vector DNA.

50 ml of LB media supplemented with Kanamycin (5

~g/ml)

was innoculated with a

sinnle SuperCos clone. The cuHure incubated overnight at 37'C with shaking at 200
rpm. The culture was ce;·,trifuged for 10 minutes at 4°C. The pellet was resuspended
in TEG swelling buffer to which 10 ml of alkaline SDS was added. The sample was
incubated on ice for 10 minutes after which 7.2 ml of high salt neutralisation buffer (3 M
KOAC) was added. The sample was centrifuged for 10 minutes at 4°C and at 13
000 rpm. The supernatant was poured through a sterile gauze into a fresh tube and an
equal volume of isopropanol was added. The sample was again centrifuged for 10
minutes at 4°C and at 13 000 rpm. The supernatant was discarded and the pellet
resuspended in 2 ml of nuclease free water. 2 ml of LiCI was added to the sample
and incubated on ice for 10 minutes. DNA was extracted by the phenoVchloroform
method and centrifuged for 13 000 rpm for 5 minutes at room temperature.

The

phenoVchloroform method of DNA extraction involves extraction with a phenolchloroform-isoamyl alcohol (25:24:1) mixture saturated with 50mM Tris-HCL (pH 8.0)
followed by extraction with chloroform. The aqueous phase was adjusted with 0.3 M
NaOAc (pH 5.5) and ethanol-precipitated. The pellet was washed with 70%(w/v)
ethanol and the ethanol wash was removed and the DNA pellet air dried for 5 minutes
and resuspended in 400 IJI of 1X TE. 41JI of RNAase A (10mg/ml stock) was added
to the sample which was incubated for 15 minutes at 37°C. The sample was divided
into 4, 50 111 samples.

Three of these samples were re-extracted by different

methods, the final sample was not treated further.

The first re-extraction method was phenol choloroform extraction as described above.
The second re-extraction was by ethanol precipitation as described in Section 3.2.2
(pp. 42). The third re-extraction was by Oiquick purification as described in Section
2.2.2.1 (pp. 31 ). All samples were resuspended in 50 pi of nuclease free water
(exceplltle untreated sample which was already in 50 pi of nuclease free water. The
concentration and purity of the isolated superCos vector DNA was assessed by
spectrophotometry and agarose gel electrophoresis as described in Section 2.2.1.4
(p. 26) and 2.2.1.5 (p. 27).

4.2.1.2

Digestion and Dephosphorylation of Vector DNA

50 pl. 60 pg of Supercos 1 cosmid vector (Sample B) extracted by ethanol
precipitaion was tlige,!ed with 200 U Xba1 at standard buffering conditions (25 pi of
10 x multicore buffer) and dephosphosphorylated with 5 units of SAP to a total
volume of 250 111 with nuclease free water. The sample was incubated at 37°C for 1
hour. The reaction was adjusted to 15mM EDTA to inactivate the Xba1 followed by
incubation at 68°C for 10 minutes to inactivate the SAP.

The sample was ethanol

precipitated and resuspended in 50 f.!l of nuclease free water.

A 5 pi aliquot was then electrophoresed on a 0.5% (w/v) agarose gel to check for
complete digestion of the cosmid vector which was recognised as a single linear
cosmid band of 7.6 kb.

4.2.1.3

Digestion of Xbal- and SAP-treated DNA with BamHI

Twently five micrograms (21f.!l) of the Xba 1- and SAP-treated vector DNA was
digested with 5 U/f.!g of BamH I enzyme in a total volume of 250 pi at standard
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buttering conditions (25 ttl ot 10 x multicorc butter) for 1 hour at 37"C. The DNA was
ethanol-precipitated and resuspended in nuclease free water to a concentration of

1.0ttgipl.

4.2.2

4.2.2.1

Preparation of Genomic DNA

Partial Digestion and Dephosphorylation of Insert DNA

As large DNA inserts were required for cloning into the cosmid vector, the manufacturer
recommended that genomic DNA must be -150 kb before digestion. The genomic
DNA extracted from the GR dogs 19C5 and 6800 (see, Section 2.2.1, p. 24) were
considered to be larger than 50 kb and therefore adequate for this application. Utmost
care was taken throughout the digestion of the genomic DNA during both mixing and
ali quoting steps, gentle inversion and gentle pipettling with wide bore tips to prevent
shearing of the DNA.

In order to clone into the BamH I site of the ot the SuperCos 1 vector the genomic
DNA was partially digested with Sau3A I. Using extracted genomic DNA (section
2.2.1, p. 24) two trial digests using 0.5 U and 0.1 U ot Sau3A 1 were constructed to
determine the ideat conditions for obtaining the desired insert size range ot 30 to 42
kb. Ten micrograms of genomic DNA, 10 pi of 10 x multicore buffer, 1 pi Bovine
serum albumin (BSA), in a final volume of 100 pi made with nuclease free water was
pre-equilbrated at 37"C for 5 minutes before the 0.5 U or 0.1 U of Sau3A 1 was
added.

During various time points of 0-, 5-, 10-, 15 minutes, 15 ttl aliquots were

removed from the reaction. To these samples 6 x GLB loading buffer was added
and the samples electrophoresised on a 0.5% (w/v) agarose gel.

After the optimal time interval of the digestion had been determined, a Iorge scale
partial digestion of 50 Jtg of genomic DNA was then performed in a total reaction
volume of 500 pl. The reaction was scaled up to best mimic the test conditions of the
partial digest including enzyme concentration, temperature and reaction time.

Also

included in the large scale digestion was 2 U of SAP. After digestion the sample was
ethanol precipitated and resuspended in 25 pi of nuclease free water.

A 0.1 Jll of the

large scale digests were electrophoresised on a 0.5% (w/v) to check for digestion
compared to undigested A DNA marker.

4.2.3

Ligation of Insert DNA and the SuperCos 1 Vector

The ligation was constructed by adding the following components to a eppendorf
tube: 2.5 Jlg of the partially digested SAP genomic DNA, 1.0 111 of the SuperCos 1
DNA (Xba-SAP and digested with BamH-1[1 Jlg/Jll]} was added to 2.0 Jll 10 x ligase
buffer (Promega) in a final volume of 20 pi made with nuclease free water. A 2 pi
aliquot was removed and placed at 4°C and stored for gel analysis. To the sample
0.3 U of T4 ligase (supplied by Promega) was added and left to ligate overnight at
14°C. The T4 ligase buffer supplied by Prornega did not contain polyethylene glycol
(PEG) which can inhibit packaging.

4.2.4 Packaging

4.2.4.1

The Gigapack Ill XL Packaging Extract and Protocol

Packaging extracts are used to package recombinant phage with high efficiency. The
single tube lormat of Gigapack Ill packaging extract, simplifies the packaging
procedure and increases the efficiency and representation of libraries. The Gigapack Ill
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XL packing extract supplied by Stratagene is designed for usc in genomic cosmid
library construction and can preferentially package 47- to 51 kb recombinants.

The Giga pack Ill XL packing extract was removed from -80°C storage and placed on
dry ice. The packaging extract was quickly thawed and the experimental DNA (1-4 Ml
containing

0.1-l.O~g

ligated genomic and vector DNA) was combined with the

packing extract. The tube was stirred with pipelle lip and then incubated at room
temperature for 2 hours.

Following incubation, 500

~I

of SM buffer and

chloroform were added to the sample and the contents gently mixed.

20~1

of

The sample

was then centrifuged briefly to sediment the debris. The supernatant was then ready
for titering.

4.2.4.2

Gigapack Ill Packaging Extract Efficiency Test

4.2.4.2.1

Preparation of Host (VCS257) Bacteria

Cells from the VCS257 host strain bacterial frozen glycerol stocks were revived by
scraping off splinters with a sterile tip and streaking them on to LB agar plate which was
placed at 37°C and incubated at overnight.

Fifty millilitres of LB broth supplemented with 0.2% maltose and 10 mM MgSO, in a
sterile flask was inoculated with a single colony of the VCS257 host strain. The flask
was then placed at 37"C for 4 to 6 hours until the cells reached an OD600 of 0.5. These
cells were centrifuged in a falcon tube for 10 minutes at 2000 rpm and the cell pellet
resuspended

n 15 ml of

sterile 10 mM MgSO,. Cells were then diluted to a final

OD600 0f 0.5 with 10 mM MgSO, and stored until use a! 4°C

4.2.4.2.2

Efficiency Test Protocol

The frozen wild type lambda control DNA (k1857 sam?) was t11awed on ice and
gently mixed.

Using 1 ttl of the wild type lambda control DNA (--0.2 pg) two

consecutive 1o·' dilution's of the packaging reaction were made in SM buffer to yield a
10·' dilution of the packaging reaction. Ten microlitres of 10~ dilution was added to 200
ttl the VCS257 host strain (producing an effective 4.8X10' dilution of the packaging
reaction) and incubated at 37°C for 15 minutes. To the sample 3 ml of of 0.7% top
agar (approximately 48°C) was added and the mixture poured onto a dry re-warmed
LB agar plate. The plate was then incubated overnight at 37'C. Phage growth was
stopped wrrh 1 ml of SM buffer.

Approximately 400 plaques per plate were

expected from the 210 ttl mixture of packaging reaction and VCS257 host strain
plated out.

4.2.5 Titering the Unamplified Cosmid Library

A fresh overnight cuijure of XU-Blue MR host cells was prepared as in Section
(4.2.4.2.1, p. 60). Two dilutions, 1:10 and 1:50 of the unamplified library was made

n

sterile SM buffer. Twenty-five microlitres of the two dilutions were mixed with 25 pi of
the XU-Blue MR host cells and incubated for 30 minutes at room temperature. 200 ttl
of the LB media was added to each sample and placed at 37"C for 1 hour with gentle
shaking at each 15 minute intervals. The microfuge tube was centrifuged for 1 minute
and the pellet resuspended in 50 pi of fresh LB media. Using a sterile spreader, the
cells were plated on LB plates supplemented with 50 pg/ml amplicilin. The plates
were then placed at 37"C and incubated overnight.

4.2.6 Amplifying Cosmid libraries

I >I

In a series oi6X15 ml culture tubes, the following was added: 80 pi of the SuperCos
canine genomic library, 70 pi of SM buffer and 100 ttl of XU-Blue MR host cells. The
samples were incubated at room temperature for 30 minutes.

Four volumes of LB

broth was added to each sample and the lubes placed al 37"C for 1 hour with shaking
at 200 rpm. Each sample was plated out onto 150 mm-LB amplicillin plates and
incubated overnight at 37°C. 3 ml of LB broth was poured onto each plate and the
colonies scraped off and pipelled into a 50 ml falcon lube.

To this sample sterile

glycerol was added to a final concentration of 20% and ampicillin was added to 50
flg/ml. The sample was mixed lhroughly and 1 ml aliquoted into individual sterile 1.5
ml screw capped tubes and stored at -80.°C.

4.3.2 Titering Amplified Cosmid libraries

One of the 1 ml aliquots of the canine genomic DNA cosmid library of GR dogs 19C5
and 6800 were removed from -80.°C and placed on ice. A 1:10 and 1:25 dilution
were created in LB supplemented with ampicillin (50 fll/ml) and plated out on to LB
plates using a sterile spreader. The plates were incubated overnight at 37°C.

The

colony fomning units per millilitre (cfu/ml) of each library was calculated.

4.3.8 Integrity of the Cosmid Library

The integrity of the canine genomic DNA cosmid library was assessed by amplifying
exons 6, 10, 52 and 53 from the dystrophin gene using conventional PCR (Section
3.2.5.1, p. 44). Primers are shown in (Table 4.1 ). A positive control was constructed
for each of the exons using pre-existing genomic DNA from a nomnal male G R (Chip
number 711 ). The PCR reaction products were then electrophoresised on a 2% (w/v)
agarose gel, stained with ethidium bromide and photographed for analysis.
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Table 4.1: Primers used to Amplify Canine Dystrophin Exons 6, 10 52 and

53

Ex on

4.3

Primer

Sequence 5' to 3'

Expected size
of amplification
products
173 bp

6

Can6F
Can6R

GTCAAAAATGTAATGAAAAATATCAT
CTATGACTATGGATGAGAGCATTCA

10

Can10F
Can100R

CCT GGA GAG TTA TCA AAC AGC
AATCTCTCCTTGGGCTTGGAG

90 bp

52

DMD Ex52F
DMD Ex52R

AATGCAGGATTTGGAACAGAGCCGTCC
TTCGATCCGTAATGATTGTTCTAGCCTC

110 bp

53

DMD Ex53·F
DMD Ex53-R

TTG AAAGAA TTC AGAATC AGTGGG ATG
CTT GGT TTC TGT GAT TTT CTT TTG GAT TG

210 bp

RESULTS

4.3.1 Preparation of SuperCos Vector DNA

Spectrophotometry of the SuperCos 1 vector DNA isolated from the different
extraction methods is shown in Table 4.2. The phenol/chloroform extraction method
failed to isolate the SuperCos vector DNA. This failure was probably the resuij of the
loss of the DNA pellet during one of the ethanol washes.

For the other extraction

methods the purity was consistent while concentration ranged from approximately
291 to 610 119iml.

OD 26 ~,,

was 1.9 for all four samples.

Table 4.2:

Concentration and Purity of Extracted Vector DNA.

Extraction method

00260/280

Concentration
(~g/ml)

Phenol/Chloroform
Ethanol Precipitation
Oiaquick Purification
Untreated

0.0
1.9
1.9
1.9

0 .0
291 .2
553 .5
613 .0

Agarose gel electrophoresis of these samples revealed the presence of RNA
contamination in both the Oiaquicked and untreated SuperCos vector DNA (Figure
4.1 ). Complete Digestion of the SuperCos vector DNA was therefore performed on
only the ethanol precipitated sample, and successfully produced a complete digested
Supercos which was observed at - 7.6 kb.

Lanes

2 3
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4 5 6

Figure 4.1: Extraction of SuperCos 1 Vector DNA. Lane 1: SPP-1 molecular
wo;ght mar1<er. Lane 2: Phenol/chlorofom Extraction.

Lane 3:

Ethanol precipiation.

Lane 4· Qiaquick purification. Lane 5: Untreated. Lane 6: : SPP-1 molecular weight
mar1<er.

4.3.2 Digestion of Genomic DNA

Based on the optimal condition indicated by tlial partial digests, large scale digests
were pertormed. Optimal conditions indicated by the tlial digests for dog 19C5 was
0.1 U of Sau3A 1 at 37°C for 15 minutes while for GR do1 6800 optimal conditions
was obtained at 0.5 U of Sau3A 1 at 37'C for 10 minutes .

4.3.3 Ligations

Figure 4.2 shows the digested SuperCos 1 vector DNA and the digested SuperCos
1 Vector DNA with

GR Genomic DNA (complelely digested) before and after

ligation with T41igase. Lones 2 and 4 show that ligation worked. The 'bands' in these
lanes were shifted upwards relative to lhe control lane of 1. Of note was the fact that
ligation still worked in the presence of GR genomic DNA (see, lane 4).

',!

Lane

1

2

3

4

5

Figure 4.2: Li gations of SuperCos Vecto r DN A and the SuperCos Vector DNA with
GR Genomic DNA . Lane 1: Complete Digest of SuperCos Vector DNA before
Ligation. Lane 2: Complete Digest of SuperCos Vector DNA after Ligation . Lane 3:
Complete Digest of SuperCos Vector DNA with GR genomic DNA before Ligation .
Lane 4: Complete Digest of SuperCos Vector DNA with GR genomic DNA after
Ligation. Lane 5: Undigested A, marker.

4.3.4 Packaging

The packaging control showed 100% eficiency with
counted on the LB plate.

Titering

approximately 400 plaques

of the amplified GR genomic cosmid

library

showed that the efficiency of the packaging of the recombinants was not as effective
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with only 21 and 22 clones observed at the 1:1 0 and 9 and 11 clones observed at
the 1:25 dilutions for GR dogs 19C5 and 6800 respectively.

4.3.5 Integrity

The intergrity of the library was assessed by PCR for exons 6, 10 , 52 and 53. All
exons were present in the positive GR genomic DNA control. Only exons 10 and 52
amplified in the GR cosmid libraries constructed in this project. Further optimisation to
amplify exons 6 and 53 by decreasing and increasing the annealing temperature from
55°C to 50°C and from 55°C to 58°C, respectively and varying the amount of target
through dilution failed to produce any significant products. The dystrophin gene in the
two GR genomic DNA cosmid libraries constructed in this experiment was, therefore,
most probably under represented. Screening for the intronic boundaries surrounding
exon 6 by conventional hybridisation was therefore abandoned.

Lanes

1

2

3

4 5

6 7

8
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9 10 111213 1415

•

As lhe samples had run below 1110 SPP-1 molewb woighl marker an <Jhquot of
the Amplilcation products were clcctrophoreslcrJ on

fl

3% agarose gel (w/v) for

BOV for 40 minutes. All exons corresponded to expected sizes.

Figure 4.3: Amplification of Canine Dystrophin Exons 6, 10, 52 ilnd 53 I rom
the two GR Cosmid Libraries. Lane 1: SPP-1 Molecular weight marker. Lane 2:
10 ng of GR 19C5 Cosmid Library. Exon 6. Lane 3: 10 ng of GR 19C5 Cosmid
Library, Ex on 10. Lane 4: 10 ng of GR 19C5 Cosmid Library, Ex on 52. Lane 5: 10
ng of GR 19C5 Cosmid Library, Exon 53. Lane 6: 20 ng of GR 19C5 Cosmid
Library, Exon 6. Lane 7: :~o ng of GR 19C5 Cosmid Library, Exon 10. Lane 8: 20
ng of GR 19C5 Cosmid Library, Exon 52. Lane 9: 20 ng of GR 19C5 Cosm'1d
Library, Ex on 53. Lane 11: 10 ng of GR 6800 Cosmid Library, Ex on 6. Lane 12:
10 ng of GR 6800 Cosmid Library, Exon 10. Lane 13: 10 ng of GR 6800 Cosmid
Library, Exon 52. Lane 14: 10 ng of GR 6800 Cosmid Library, Exon 53. Lane 15:
20 ng of GR 6800 Cosmid Library, Exon 6. Lane 16: 20 ng of GR 6800 Cosmid
Library, Exon 10. Lane 17: 20 ng of GR 6800 Cosmid Library, Exon 52. Lane 18:
20 ng of GR 6800 Cosmid Library, Exon 53. Lane 19: Control GR 711 Genomic
DNA, Exon 6. Lane 20: Control GR 711 Genomic DNA, Exon 10. Lane 21: Control
GR 711 Genomic DNA, Exon 52. Lane 22: Control GR 711 Genomic DNA. Exon
53. Lane 23: PCR negative control. Lane 24: SPP-1 Molecular weight marker.

4.4

CONCLUSION

The cosmid library constructed in this experiment contained insufficient dystrophin
clones.

There are a large number of factors that could account for this under

representation: non-random distribution of restriction sites, restriction activity in the
packaging extracts, deletion of sequences by recombination, and selection against
representation of the clone of interest during amplification of the library (Sambrook et
al., 1989, p. 3.55).

CHAPTER 5.0

5.1

PCR SCREENING OF THE CANINE A LIBRARY

INTRODUCTION

In a final attempt to obtain intronic sequence for the canine dystrophin gene, a
pre-made canine genomic DNA A (FIX II) library was purchased from Strata gene.
This was constructed from beagle genomic DNA. Since rr was the only such library
available, rr was purchased on the assumption that the dystrophin exonic and intronic
sequence of the beagle and the G R dogs were identical. This assumption could be
tested, at least for exonic sequences.

The basic strategy of this experiment was to biologically amplify this library in a
multiwell plate, using a total of 96 wells, such that 3 canine genomes become available
for PCR screening. In particular, this amplified genome was to be screened for the

presence of the intron boundaries surrounding exon 6.

5.2

METHODS

5.2.1 The A FIX II Library

The A FIX II vector is a replacement vector used for cloning large fragments of genomic
DNA. '/.. phages that contain active red and gam genes are unable to grow on host
strains that contain P2 phage lysogens. A phages without these genes are able to
grow on host strains lysogenic for P2. The red and gam genes in the A FIX II DNA are
located on the stuffer fragment, therefore the wild-type A FIX II phage cannot grow a
P2 phage lysogen such as the bacterial strain XL-Biue MRA (P2). When the stuffer
fragment is replaced by an insert, the recombinant A FIX II vector becomes red/gam,

and the phage is able to grow on the P2 lyosgenic strain. Therefore, by plating the
library on the XL-Biue MRA (P2) strain, only recombinant phages are allowed to
grow. The polylinker for the AFIX II vector has T3 and T? bacteriophage promoters
which can be used for PCR amplification of inserts.

5.2.5 Integrity of A I'IX II Library: Exon 6 Assay

The integrity of the A FIX II unamplified library was tested for exon 6 prior to PCR
screening of the multiwell plate. Two approaches were adopted: conventional PCR
using: Tth DNA

polymerase

(Biotech International): and Platinum

Taq DNA

polymerase (GibcoBRL, 1999b). The primer set shown in Table 5.2 was used to
amplify an ex on 6 product of approximately 90 bp from the unamplified A FIX II
Library. The components of the conventional PCR using Tth DNA polymerase is
outlined in Table 5.1.

Table 5.1: Components of Conventional PCR

Component

Volume

Sterile water
5.2 100

16.9
5

Primers (50ng/f..d)

2

T. th DNA polymerase (S.SU/ul)
Target DNA (verious dilua)
TOTAL

0.1

lull

Final concentration
1x PCR buffer, 2mM MgCI 2 +
100uM dNTP's
4 ng/~11
0.22 U/ul

25

Table 5.2: Exon 6 Primers
Primer

Primer Orientation

Sequence 5' to 3'

Can6F

Forward
Reverse

GTCAAAAATGTAATGAAAAATATCAT
CG(NG)ACCCAGCTCAG(NG)AGAATC

Exon 6/R
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Thermal cycling was performed under the conditions described in Section 3.2.5.1 (p.

44). The PCR reaction products were then electrophoresed on a 3% agarose gel.
stained with ethidium bromide and photographed for analysis.

Optimization was

attempted by: varying annealing temperature over the range 50'C-60'C; and by
varying the volume of the library target DNA added to the PCR from 1 111 -> 0.01 11!
(by dilution).

Platinum Taq DNA polymerase (GibcoBRL, 1999b) was then used as the enzyme
to attempt this amplification. Its hot start, which acts to increase sensitivity, specific'1ty
and yield were considered possibly advantageous for the optimization of this PC R.
To improve the liklehood that exon 6 would be amplified with Platinum Taq DNA
polymerase, 5 ng, 25 ng, 50 ng and 250 ng masses of genomic DNA were used as
targets. In addition 1 and 5 111 aliquots from the unamplified library were also used as
target in this PCR series. The components of the Platinum Taq reaction are outlined i1
Table 5.3.

Table 5-3: Components of the Platinum Taq PCR reactions

Component
Sterile water
10x PCR Buffer
SOmM MgCI2
SmM dNTPs
Primers (5Dngi1JI)
Platinum Taq polymerase
(5.5 Ulull

Volume (ul)
17.4

2.5

Final concentration
1x

2mM
1

200~1M

2
0. 1

0.22 U/Jll

Target DNA

TOTAL

25

Thermal cycling was performed under the same conditons as conventional PCR (see,
p. 44).

The PCR reaction products were then electrophoresed on a 3% (w/v)

agarose gel, stained with ethidium bromide and photographed for analysis.
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5.2.3

Amplifying the Phage Library

Screening of this library was based on a modiF,;d version of the Hughes (1998)
protocol for arraying bacteriophage "!..libraries for screening by PCR. Hughes protocol
involved the transfer of phage particles on to a gridded nylon membrane.

This

membrane was then divided up into individual pieces and placed in multiwell plates.
Phage particles were eluted into SM buffer for pooling and screening by PCR. This
novel method involved the amplification of the "!.. library in liquid suspension in a 96
well PCR plate for pooling and screening by PCR.

In the modified technique reported here, the gridded nylon membrane was eliminated
in the interests of economy and because there seemed to be a risk of cross

contamination as the nylon rnembrane was cut into cm2 pieces. Phage rarticles were

simply amplified in the multiwell plates.

The complexity of the canine library was provided at 6 x 1O' plaque-forming units per
millilitre (pfu/ml). To reduce the iabour of screening for single positive clones. library
complexity was reduced to 3 canine genomes, spread over 96 wells in a single
multiwell plate. A 3x10 3/~l (3000 phage per welt) dilution of the unamplified library
was made in sterile SM buffer. To each well of the 96 well plate, 1 Jll of 3x10. 3/pl
dilution was added to 100

~I

of host XU-Blue MRA (P2) cells (00 600

~

0.1) as

prepared using same procedure as section 4.2.4.2.1 (p. 60). The plate was then
incubated at room temperature for 15 minutes. 200 pi of sterile LB medium was then
added to each well and the plate was covered with a plastic cover to prevent inter-well
contamination and left at 37"C with gentle shaking overnight.
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5.2.4

Titering the Library Array for Amplification

To check the library array for amplification, 1 ttl of the diluted phage (3x1 0'/~1) and 1 ~I
from 5 randomly picked wells across the plate were combined with 9 ~I SM buffer and
200 ttl of host bacteria and incubated at 37°C for 15 minutes. Following incubation,
3 ml of 0.7% top agar, at approximately 48°C and supplemented with 10 m M
MgSO,, was mixed with each sample and poured on to pre-warmed LB plates
supplemented with 10 mM MgSO,.

The plates were then incubated at 37"C

overnight. Plaques were counted to con finn amplification of the library array.

5.2.5 Screening with Pt01tinum Taq PCR

Five microlitres of chlorofonn supplemented with sodium hydrogen carbonate was
added to each well and left at room temperature for 15 minutes with gentle shaking.
The cell debris was allowed to setlle for 30 minutes.

A strategy of pooling well contents was adopted to reduce, from 96 to 20, the number
of exon 6 screening PCRs that would be required. This was achieved by dividing the
96-well plate into twelve columns labelled t to 12, and eight rows labelled A to H
(see, Figure 5. t, p. 74). Five microlitres from each well in a row was sampled and
pooled into a single well.

This gave 8 pooled samples (labelled A-H), each

containing 12 phage amplifications. Columns were pooled in a similar fashion to give
12 pooled amplifications (labelled 1-12), all containing 8 phage amplifications (see
also, Figure 5.1 ). Since the screening of the genomic FIX II library showed Platinum
Taq DNA polymerase amplification Ia be most successful with this library, rt was the

amplification method employed to screen all pooled samples.

The reaction

components and cycling conditions employed are described in section 5.2.2 (p. 70).
A positive control was set up for exon 6 using 5;11 of the unamplified library.
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Figure 5.1 : Pooling Strategy of the Amplified Multiwell Plate.

Screening of positive well(s) was perform ed using combinations of an exon specific
primer with either the T3 or the T7 vector primer. An inspection of the PCR product
size indicates the orientation of the cloned fragment. The T3 and the T7 vector primers
are shown in Table 5.4.

Table 5.4: Tl and T3 primers

Primer
T3 promotor
T7 promotor

Primer Orientation
Forward
Reverse
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Sequence 5' to 3'
T AAT ACGACTCACT AT AGGG
AATT AACCCTCACT AAAGGG

5.2.6 Screening with Elongase PCR

Exon 6 may be located in cloned lragments too far I rom T7 and/or T3 primers lor
amplification by Platinum Taq polymerase. Its maximum range is approximately 3 kb.
To cover this possibility. positive ex on 6 clones which Platinum Taq polymerase !ailed
to amplify with either T3 or T7 primers. were tested using ELONGASE.

The

conditions that were employed were described in Section 2.2.2 (p. 28).

5.2.7

Sequencing of Exon 6 Boundaries

PCR products to be sequenced were first purilied by the Qiaquick purilication sy>tem
as previous described in Section 2.2.2.1 (p. 31 ). Following purilication, a Sui aliquot
was run on a 2% agarose gel and the intensitiy compared to the DNA markers. The
sequencing reaction and analysis of results were periormed as outlined in Section
2.2.2.2 (p. 32).

5.3

RESULTS

5.3.1. Integrity of the J. FIX II library: Exon 6 Assay

Despite 17 attempts at optimising conventional PCR using Ttil DNA polymerase, this
approach failed.

Fortunately, attempts to amplify exon 6 lrom the canine (GR)

genomic DNA and the unamplified A FIX II library using Platinum
polymerase, all succeeded. These results are shown in Figure 5.2 (p. 76).
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Taq DNA

Lane 1

2

3

4

5

6

7

8

9

Figure 5.2: Optimization of PCR using Platinum Taq to Amplify exon 6 from
both Genomic DNA and the Undiluted Phage Library. Lane 1: 200 ng DMW 1OOM molecular weight marker. Lane 2: pUC molecular weight marker. Lane 3: 5 ng
of genomic DNA.. Lane 4: 25 ng of genomic DNA. Lane 5: 50 ng of genomic DNA.
Lane 6: 250 ng of genomic DNA. Lane 7: 1 1-11 of the undiluted lambda library. Lane
8: 5 1-11 of the undiluted lambda library. Lane 9: Negative control

5.3.2 Titering the Library Array for Amplification

All 5 wells randomly picked from the multiwell plate, gave total lysis of phage following
overnight incubation, indictating that amplification of the multiwell plate had taken place
and that PCR amplification was possible.
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5.3.3 Identification of Positive Wells

Platinum Taq amplification (Section 5.2.2) for exon 6 from the pooled wells A to H
indicated that a well in row 8 was positive for exon 6 (see Figure 5.3, p. 77), while
amplifcation of the pooled wells 1 to 12 indicated that a well in column 10 was positive
for exon 6 (see, Figure 5.4, p. 78). Using these positive co-ordinates, only one well,
108, contained ex on 6 (see, Figure 5.5, p. 78).

Screening of well 108 was

performed with the exon 6 forward primer and with either the T3 or T7 vector primers
(see , Figure 5.6).

Amplification of the exon 6 forward and T7 vector primer set

produced a PCR product of 1.3 kb (Figure 5.6) .

Lanes

1

2

3

4

5

6 7

8

9 10 11 12

Figure 5.3: PCR Screening of the Pooled Wells A to H from the Library
Array. Lane 1: 200ng DMW-1OOM molecular weight marker. Lanes 2 to 9: pooled
wells A to H. Lane 10: Positive control exon 6 from undiluted library. Lane 11:
Negative control. Lane 12: 200ng DMW-1 OOM molecular weight marker.
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9 10 11 12 13 14 15 16 17

Figure 5.4: PCR Screening of the Pooled Wells 1 to 12 from the Library
Array. Lane 1: 200ng DMW- 1OOM molecular weight marker. Lane 2 to 13 : Pooled
wells 1 to 12. Lane 14: Positive control exon 52. Lane 15: Positive control exon 6
from undiluted library. Lane 16: Negative control. Lane 17: 200ng DM W-100M
molecular weight marker.
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Figure 5.5:

Multiwell plate Showing the Positive Well (1 08) Containing

Exon 6.

Lane

1

2

3

4

5

6

Figure 5.6: Amplification of Exon 6 Forward with T7 and T3 Vector Primers
Focusing on Well 108 from Library Array. Lane 1: 200 ng DMW-1OOM molecular
weight marker. Lane 2: Exon 6F with T3. Lane 3: Exon 6F with T7. Lane 4: Exon
6 positive control. Lane 5: negative control. Lane 6: 200 ng DMW-1 OOM.

Amplification of exon 6 with the exon 6 reverse primer and the T3 vector primer set
was attempted by Platinum Taq polymerase.

This approach failed to produce any

significant products. The amplification of the same primer set was performed with
ELONGASE. This approach also failed to produce any significant PCR products.
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I
5.3.4 Sequencing

The PCR product obtained by the exon 6 forward and T7 primer set was purified by
the Qiaquick protocol and an aliquot was electrophoresed to determine the integrity
and intensity for sequencing. A discreet band was observed at 1.3 kb and was
approximately the same intensity as the band corresponding to 1 kb on the 100 b p
ladder. Two microlitres of this purified product was used as template for sequencing
with only the exon 6 forward amplification primer. The sequence of the 5' splice site of
intron 6 was obtained.

The chromatogram of this exon 6 I intron 6 boundary is

illustrated in Figure 5.7 (p. 81). A 2'-0-methyloligonucleotide was designed to block
this exon/intron boundary to induce skipping of exon 6 is also illustrated in Figure 5.7
(p. 81). This AO is yet to be ordered.

5.4

CONCLUSIONS

Platinum Taq DNA polymerase amplification was successful in amplifying ex on 6 from
both genomic DNA (GR) and from the unamplified canine A. FIX II library.

Growth of the A FIX II library in liquid suspension on the multiwell plate was successful.
The modified method pioneered here offers unique advantages over the Hughes
method. It saved money and time and avoided the possibility of cross contamination.
The PCR screening of the A. FIX II library using the pooled well strategy, successfully
identified a positive well containing exon 6 positive clones.

The amplification of the positive well using Platinum Taq DNA polymerase with the
exon 6 forward and T7 vector primer successfully amplified a t .3 kb PCR product that
gave a possible intronic stretch for sequencing. Sequencing of this product identified
the canine 5' splice site of intron 6.
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CHAPTER 6.0:

6.1

As

AO TRANSFECTION STUDY

INTRODUCTION

the

project

reached

its

conclusion

the

availability

ol

the

2'·0·

methylribooligonucelotide complementary to the 5' splice site of intron 8 permitted a
""one shot"' transfection study. This translection study was designed to deliver the AO to
cu~ured

primary muscle cells derived from the normal GR dog.

This AO should

hybridise with its complementary mRNA sequence and induce skipping of exon 8
during splicing of the canine dystrophin gene.

As this transfection experiment was the first of its kind on cultured GR myoblasts. the
transfection conditions were based on optimized conditions developed

for the

transfection of mdx myoblasts.

6.2

METHODS

6.2.1 AO Delivery Systems

Two transfection reagents were used. Lipofectin and LipofectAMINE (LF2000) both
supplied by GibcoBRL.

LIPOFECTIN reagent is a 1:1 (w/w) liposome formulation ol the cationic lipid N-[1·(2.3·
dioleyloxy)propyl)·n.n.n-trimethylammonium
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choride

(DOTMA).

and

dioleoyl

phospholidylelhanolamine (DOPE) in membrane fitered water.

It rs suitable for the

transfection of DNA into tissue culture cells.

LF2000 is a new proprietary formulation that has been found to have the nighest
trasfection efficiency in many cell types.

6.2.2 Pimary GR Myoblast Culture Preparation

The normal primary myoblast cunure was approximately 90% confluent after two days
of incubation at 37"C with 5% C0 2 in proliferation media: 20% foetal caff serum (FCS),
0.5% Chick embryo extract (GEE) and Hams F1 0 media. This proliferation media was
removed 3 hours prior to transfection and replaced OPTI-MEM and incubated at 37"C
with 5% CO,. Once the transfection mixtures were ready to add to the normal primary
myoblast culture, the differention media was removed.

6.2.3 AO Transfection

As two different transfection systems were used in this project the 24 well cunure plate
containing the primary myoblast cunure was divided so that each reaction condition was
made in duplicate, except for the controls.

6.3.4.1

Lipofectin Transfection

The lipofectin transfP.Ction experiment was constructed using two transfection ratios, 1:2
and 1:5, of AO to transfection

reagent.

constructed (Table 6.1 ).
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A lipofeclion reagent control was also

I
The lipofectin translection protocol consisted ollwo solutions, A and B (Table 6.1).
Solution A was constituted by adding the lipofectin to the Opti-MEM. The solution was
mixed thoroughly and incubated at room temperature for 45 minutes.

Following the

incubation period Solution B was consli!uted and combined with the solution A.

This mixture was mixed gently and incubated at room temperature for 10 to 15 minutes.
800 t.d of HAMS FlO supplemented with 5% FCS was then added.

500 ~I ol this

mixture was subsequently added to each of the two wells containing the primary G R
myoblasts.

Table 6.1: Components of the /ipofectin Solutions A and 8

Ratio of AO to lipofeciin reagent

Solution A
Solution 8

6.2.3.2

1:2

1:5

Upofectin Control

(made two)

(made two)

(made one)

8.8 IJI Upofectin

22 Jll Lipofectin

92 Ml Opti·MEM

78 Ml Opti·MEM

22 1-11 Lipofectin
78 Ml Opti·MEM

4.4 M9 AO
96 ul Ooti·MEM

4.4 M9 AO
96 ut Ooti-MEM

100 t Ooti-MEM

LF2000 Transfection

The LF2000 lransfection experiment was constructed using two transfection ratios, 2: 3
and 1 :2, of AO to transfection reagent. A LF2000 reagent control was also constructed
(Table 6.2).

The LF2000 protocol consisted of two solutions, A and B (Table 6.2). Solution A was
constituted by adding the LF2000 reagent to the Opti-MEM.
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The solution was mixed

thoroughly and incubated at room temperature lor 5 minutes. Following lhc incubation
period Solution B was constructed and added to Solution A.

The mixture was then

incubated for 20 minutes. 800 pi of HAMS F10 supplemented with 5% FCS was
added to the minture and 500 pi of this mixture was subsequently added to each of the
two wells containing the primary GR myoblasts.

Table 6.2: Components of the LF2000 Solutions A and 8

Ratio of AO to LF2000 Reagent

2:3
(made two)

1:2
{made two)

LF2000 Control
(made one)

Solution A

6.6 Jll Lipofectin
94 ~I Opli·MEM

8.8 Jll Lipofectin
92 Jll Opti-MEM

8.8 )11 Lipofectin
92 ~I Opti·MEM

Solution B

4.4 ~gAO
96 ul Qpti-MEM

4.4 ~tg AO
96 ul Opti·MEM

100 ul Qpti·MEM

6.2.3.3

Controls

6.2.3.3.1

AO Control

The 2'-0·methyloligoribonucleotide designed to target the 5' splice site of intron 8 was
syntheized by Geneworks.

This AO was resuspended in sterile water to a final

concentration of 1 flg/pl.

1 ml of HAMS F1 0 supplemented with 5% FCS was added to 4.4 ftl (or 2.2 rtl per
well) of the AO. 500 pi of the mixture was then addedto each well.

R5

I
6.2.3.3.2

Untreated

For the untreated wells the media was removed and 500

~I

ol Hams FlO

supplemented with 5% FCS was added to each well.

When all samples had been added to the wells. the culture dish was then incubated for
20 hours at 37"C with 5% CO,.

6.2.4 Total RNA Extraction RNAzol B

Total RNA was extracted lrom primary cultured myotubes using RNAzol B (Tel Test)
as described by the manufacturer.

The media from each reaction condition (two wells) was removed.
pooled to obtain a suitable quantity of RNA. 300

~I

These wells were

of RNAzol B was added to the first

well and mixed thoroughly. This mixture was transferred to the second well and mixed
thoroughly again to ensure a thorough lysing of the cells. The 300

~I

of RNAzol B

containing the cell extracts was transferred to a sterile eppendori tube and 30

~I

of

chloroform was added. The sample was vortexed thoroughly and incubated for 15
minutes at 4"C followed by centrifugation at 13 000 rpm for 15 minutes at 4"C.

Atter

centrifugation, the aqueous phase (containing the RNA) was removed and placed into a
fresh 1.5 ml eppendori tube to which an equal volume of isopropanol was added. This
sample was vortexed thoroughly and incubated for 15 minutes at 4 "C followed b y
centrifugation at 13 000 rpm for 15 minutes at 4"C. The supernatant was removed from
the RNA pellet and 150

~I

of 100% ethanol and 50 til of 0.3 M sodium acetate (pH

5.2) was added. The tubes were placed at ·BO"C for 5 to 10 minutes and centrifuged at
13000 rpm for 15 minutes at 4"C.

The supernatant was carefully removed and the

RNA pellet washed in 100 pi of 75% ethanol followed by immediate centrifugation at
13 000 rpm for 10 minutes. Alter removing the 75% ethanol wash, the pellet was air
dried under a tissue (to avoid contamination from the air) for 15-20 minutes until all
residual moisture had evaporated. The RNA sample was then resuspended in 40 pi of
RNase-free water.

6.3.4.1

Spectophotometry

Spectopholomelry was performed on 5 pi of RNA in 55 pi of water (1/12 dilution). An
OD" 0 value of 1.0 represents a concentration of 40ng/fll of RNA. The concentration of
the RNA sample was determined as follows:

Concentration of RNA (Jig/mli = OD 260 x dilution factor X 40

The ratio of OD"0 " 80 of 2.0 was assumed Ia represent pure samples of DNA.

6.2.5. Reverse Transcriptase PCR (AT-PCR)

The Trtan expand kit supplied by GibcoBRL is a one tube system allowing i°C R
amplification to oocur in the same tube following eDNA synthesis by the reverse
transcriptase.

Primary amplification of the RNA extracted from the transfected G R

primary myoblast was performed form exons 1 to 10.

Components of the Trtan

reaction are described in Table 6.3. Primers for the amplification of exons 1 to 10 are
shown in Table 6.4.
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Table 6.3: Components of the Titan Expand RT-PCR

Component
Sterile Water

Volume {1tl)

on (toomM)

AT-PCR 5X Buffer with Mg~'

dNTP's (5 mM)

3.125
0.625
2.5
0.5
1.5

Primer mix (25 ng/ul)
Enzyme mix
Target ANA

0.25
4

Total

Final Concentration

smM
1X (1.5 mM MgCI?)

0.2mM
1 .5 ng/ul
No! specified
-4 ng/ul

12.5

Table 6.4: Primers used to Amplify Canine Dystrophin Exons 1 to 10

Thermocyling was performed under the following conditions: 25'C for 2 minutes. 48'C
for 30 minutes, 94'C for 2 minutes followed by 45 cycles of 94'C for 15 seconds,

55'C for 1 minute and 72 'C for 2 minutes.

Amplified primary samples w"re fraclionalised by agarose gel electrophoresis and
visualised by UV transilluminat;on.

6.2.6 Secondary PCR Amplification

Secondary ampl~ication was performed using a 1~I aliquot of the primary PCR pro duels
and re-amplified in a 50 ul reaction using the nested primer sets to amplify dystrophin
exons 5 to 10 and 5 to 9. These primers sets are shown in Table 6.6. The secondary

88

amplifications using conventional PCR as outlined in Table 6.5.

Tt1ormocycling was

pertormed as outlined in Section 3.3.5.2 (p. 44).

Table 6.5: Components of Secondary Amplification of PCR Products

Component
Sterile Water
5.2<'00
Primers (50
ng/ pi)
Taq (5.5 U/pl)
Target

Final Concentration

Volume (pi)
34.8
10
4

200 mM dNTP's, 2 mM MgCI?
4 ng/1-11

0.2
1

0.022 U/ J.JI

50

Total

Table 6.6: Primers used to Amplify Canine Dystrophin Exons 5 to 10 and 5 to

9

Exons

Primer

Primer Orientation

5 to 10

CanDys5F'
CanfOOR

Forward
Nested Reverse

5 to 9

CanDysSF'
ConD s9R

Forward
Reverse

Sequence 5' to 3'

GGAAATCA(CIT)AAACTGACTCTIGG
AATCTCTCCTIGGGCTIGGAG
GGAAA TCA(CIT)AAACTGACTCTIGG
CATAAGCAGCCTGTGTG AIT AGGCAT

Amplified samples were fractionalised on a 2% agarose gel and visualised by U V
transillumination.

6.3

RESULTS

X9

6.3.1 The Primary GR Myoblast Culture and Transfection

Examination ol the myoblasts prior to transfection showed signs of cell death. As a
result the transfection was done in the presence of serum but the AO-Iipofectin/LF2000
reagent complexes was done in serum free OPTI-MEM.

Observation of the plate following transfection revealed that the untreated and A 0
controls showed ittle cell death while the wells containing the lipofectin/LF2000 reagents
showed signs cell death, indicating a toxic effect of these reagents.

6.3.2 Total RNA extractions

Total RNA extractions from the transfected GR primary myoblasts using RNAzol B
ranged in purity and concentration.
shown

n Table

Spectrophotometry of the RNA extractions are

6.7. For consistency all samples wtth concentrations over tOO f!glml

were diluted 100 fjglml in RNAase free water prior to Titan RT -PCR amplification.

Table 6. 7: Concentration and Purity of Extracted RNA

Sample

Upofectin controi
LF2000 control

AO only
Untreated
Lipofectin I :2
Lipofectin 1:2
Lipofectin 1:5
Lipofectin 1:5
LF2000 1:1.5
LF2000 1:1.5
LF2000 1:2
LF2000 1:2

002601280

Concentration
ua/ml

1.8
2.2
1.9
1.8
1.8
1. 7
1.7
1. 7
1.7
1.7
1.7
1.6

11 0.4
142.3
117.2
121.6
57.1
161.7
183.6
104.1
66.4
71.9
108.8
70.8
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I
6.3.3 Titan RT-PCR

Figure 6.1 shows the primary amplification of eDNA ,exons 1 to 10 derived by reverse
tmnscription of the extracted RNA from transfected GR primary myoblasts using the
Trtan expand RT-PCR kit.

Strong amplification products were observed at 1.1 kb

corresponding to exons 1 to 10 of the dystrophin gene. A smaller 1.0 l<b was also
observed. This product corresponds to exons 1 to 10 missing exon 9 (124 bp).
fragment of - 915 bp skipping exon 8 was not observed.
observed in all amplifications except the negative
has yet to be identified by sequencing.
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The 300 bp fragment
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Figure 6.1: Prim_ary Amplification of Exons 1 to 10 from the Dystrophin Gene
of Transfected Primary GR Myoblast Cultures using Titan Expand RT -PCR.
Lane 1: DMW-1OOM. Lane 2: Lipofection control. Lane 3: LF 2000 control. Lane 4:
AO control.

Lane 5:

Untreated control.

Lane 6: Lipofectin/AO 1 :2 ratio.

Lane 7:

Lipofectin/AO 1:2 ratio . Lane 8: Lipofectin/AO 1:5 ratio . Lane 9: Lipofectin/AO 1:5 ratio.
Lane 10:

LF2000/AO 2:3 ratio.

LF2000/AO 1:5 ratio. Lane 13:

Lane 11 :

LF2000/AO 2:3 ratio. Lane 12:

LF2000/AO 2:3 ratio.

control. Lane 15: DMW-100M .

92

Lane 14:

Negative PCR

6.3.4 Secondary Amplification

Nested amplilication with the exon 5 lorward and 10 reverse primers generated strong
bands observed at 800 bp, representing exons 5 to 10, and a 700 bp lragment
corresponding to the exons 5 to 10 with skipping ol ex on 9. Only the lipolection 1:2
ratio sample showed a alternative transcript that co responded to the predicted size (483 bp) of a fragment skipping both exon 8 and 9 (Lane 7 of Figure 6.3).

Other

alternative transcripts were also observed in the LF2000 2:3 ratio of approximately 400
bp (Lane 11, Figure 6.2) and the LF2000 1:2 ratio of 200 bp (Lane 13, Figure 6.2).
These products are yet to be identified by sequencing.

To increase the specificity and sensitivity nested ampliifcation exons 5 to 9 was

periormed (Figure 6.3). A strong 600 bp product was observed in all samples except
the negative control and represented exons 5 to 9.

The smaller 500 bp product

skipping exon 9 was also observed in all samples. No alternative transcripts were
observed.
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Secondary Amplification of Exons 5 to 10 from the Dystrophin
Transfected

Primary

GR

Myoblast

Polymerase PCA. Lane 1: DMW- 1OOM .

Cultures

using

Tth

DNA

Lane 2: Lipofection control. Lane 3: LF

2000 control. Lane 4: AO control. Lane 5: Untreated control. Lane 6: Lipofectin/ AO
1:2 ratio . Lane 7: Lipofectin/AO 1:2 ratio.

Lane 8: Lipofectin/AO 1:5 ratio. Lane 9:

Lipofectin/AO 1:5 ratio. Lane 10: LF2000/AO 2:3 ratio. Lane 11 : LF2000/AO 2:3
ratio. Lane 12:

LF2000/AO 1:5 ratio. Lane 13:

Negative PCR control . Lane 15: DMW-1 OOM .
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LF2000/AO 2:3 ratio.

Lane 14 :
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Figure 6.4:
Gene
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14

Secondary Amplification of Exons 5 to 10 from the Dystrophin

of Transfected

Primary

GR

Myoblast

Cultures

using

Tth

DNA

Polymerase PCR. Lane 1: OMW - 1OOM . Lane 2: Lipofection control. Lane 3: LF
2000 control. Lane 4: AO control. Lane 5: Untreated control. Lane 6: Lipofectin/AO
1:2 ratio.

Lane 7: Lipofectin/AO 1:2 ratio.

Lane 8: Lipofectin/AO 1:5 ratio. Lane 9:

Lipofectin/AO 1:5 ratio. Lane 10: LF2000/AO 2:3 ratio.

Lane 11:

LF2000/AO 2:3

ratio. Lane 12: LF2000/AO 1 :5 ratio . Lane 13: LF2000/AO 2:3 ratio. Lane 14: 0 M W1OOM .
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6.4

CONCLUSION

TI1is was the first study to translect GR primary myoblasts culture. Problems with cell
death and the consequent requirement of serum in the translection would have aHected
the eHiecny of the translection reactions especially for the lipolectin reagent.

Spectrophotometric anaylsis of the total RNA extracted from the translected primary
myoblasts using the RNAzol B protocol was of suHicient quantity and quality lor
primary amlification by Titan RT·PCR.

Amplification of both primary and nested amplifications failed to produce consistent
alternative transcripts skipping of exon 8.

Further study is required for the transfection of the AO designed at.the 5' splice site of
intron 8 and to optimize the translection conditions for primary GR and GRMD
myoblasts.

DISCUSSION

CHAPTf:R 7.0

At the start of any new scientifK: project. a considerable amount of time and effort are
devoted to optimising protocols. It is a period of trials, mooification and more trials to
determine the best way forward. Such was the nature of the laboratory work reported

in this thesis.

it was intended to be a project whK:h did the basic research,

subsequently enabling others to progress to in vitro AO trials with GRMD dogs. For
the most part, this project was just that. Five different strategies were employed to
identify the intronK: sequences of interest, each strategy consisting of trial followed by
trial followed by even more trials as the elusive optimisation of experimental
conditions were pursued. In essence it was a shotgun approach to find out what would

work, and since four intronic sequences were discovered it has to be considered to be
a success. In fact there was enough time at the end of this project to attempt in vitro
AO·induced exon skipping 11 the GR dystrophin gene (see, Chapter 6). Although
this attempt showed little signs of success, this was not surprising. It was, after all, a
'one·off', first ever,

in vitro attempt to induce exon skipping in the GR dystrophin gene

This attempt was well beyond project expectations

a'o

indicated in the the aims of this

project (see, Aims, p. 21 ). The following sections review the strategies adopted.

7.1

Identification of GR Dystrophin lntronic Sequences

Five different strategies were tested in the search for GR dystrophin intronic
sequences. These were: long-range amplification, inverse PCR, PCR screening of a
phagemid library, construction of a GR cosmid library for hybridization screening and
PCR screening of a phage canine genomic library.

9

7 .1.1

Long-range Amplification

The lor.g range amplification of canine genomic DNA was successful in yielding inlron 8
from GR genomic DNA which. without exonic sequences. was approximately 1 .2 kb.
McNaughton et al. (1997) characterised the 1.1 kb human dystrophin intron 8, so the
fact that long·range PCR managed to amplify GR intron 8 indicates complementary

size between humans and GR for this intron. Following this line of reasoning, it was not
surprising that long-range PCR failed to amplify the GR dystrophin intron 7 given that
the human dystrophin intron is 110 kb (Nicholoson et al., 1997).

The sizes of the

human dystrophin introns 5, 6 and 9 are not known. At this stage, therefore, H is not
known ff the failure of long·range PCR to amplify these inlrons was due to their
excessive size.

7.1.2

Inverse PCR

Inverse PCR was a strategy tested, but not reported elsewhere in this thesis on
aooount of its failure to amplify any inlronic sequences of interest.

It was a valid

approach, however, and most probably only required some further optim'sation to get
it working. Inverse PCR is an extension of conventional PCR Ia allow amplification of
unknown nucleotide sequences flanking previously characterised regions, without
resorting to conventional cloning (Ochman et al., 1988).

The first step involves the

partial digestion of the genomic DNA with a suitable restriction enzyme (nonnally a
restriction enzyme with a four·based cleavage site) that almost certainly cleaves within
intron sequences, but not within the exon of interest, in order to liberate small DNA
fragments containing characterised exon sequence and its two flanking intronic regions
(Ochman et al., 1988; Hartl & Ochman, 1994; Strachan & Read, 1996). In this project
Sau3A was used to digest GR genomic DNA.
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After cleavage, the ends of the two flanking regions bound to the known sequence are
brought together by forcing tho fragment to circulariso. This is achieved by conducting
the ligations at very low DNA concentrations.

Under these conditions intramolecular

reactions are favoured rather than intennolecular ones, hence the possibility of

circularisation, followed by ligation (Ochman et al., 1988; Hartl & Ochman, 1994;
Strachan & Read, 1996).

Amplification of the uncharacterised flanking regions is then canried out utilising two
primers that hybridise to the ends of the known sequence. Inverse PCR refers to the
fact that primer orientation is reversed, primers are orientated away from the other

primer instead of towards rt, as is customary with respect to their normal orientation
PCR.

n

Because of the circular configuration of the molecule, the product of each

polymerisation can serve as a template for annealing of the opposite primer. Hence
repeated rounds of denaturation, annealing and polymerisation can result in a
exponential increase

n the

number of copies of the target sequence [ the intronic

distance between primers is not too great (Ochman et al., 1988; Hartl & Ochman,
1994; Strachan & Read, 1996). In this project GR dystrophin exon primers will be
used.

The inverse PCR attempted in this project resolutely failed to produce any
amplification products.

Alteration of PCR

reaction conditions, varying

Mg''

concentration and decreasing primer annealing temperature, all failed to yield
amplification products. This suggested that the problem lay in the ligation step and
specifically with the concentration of DNA employed.
concentrations would be a worthwhile !rial.
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Titrating ligation DNA

7 .1.3

PCR Screening of a Phagemid Library

PCR screening of the phagemid library successfully identified the 3' splice site of inlron
7. Allempls to identify the intronic boundaries of surrounding exon 6 and the 5' splice
site of intron 9 were unsuccessful. Secondary amplification using 5emi-nested exonic

primers should have increased specificity but as reported in Section 3.3.3. this failed
despite may attempts at optimising PCR conditions. This failure remains unexplained.

7.1.4

Construction of a GR Cosmid Library for Hybridization Screening

As reported in Chapter 4 a GR genomic DNA cosmid library was successfully
constructed as demonstrated by the successful amplification of exons 10 and 52.
However

~

was an under represented library because other exons failed to amplify.

The difficulties that can be encountered in the construction of cosmid libraries. and
leading to under representation, were reviewed in the Conclusion lo Chapter 4.

7.1.5

PCR screening of a Phage Beagle Genomic Library

In this strategy a phage beagle genomic library was screened for intron boundaries
surrounding exon 6 on the premise that

~would

be homologous to the GR exon 6.

This turned oullo be a correct assumption, as far as this assumption could be tested.
The beagle exon 6 sequence was found Ia be identical to the published GR exon 6
sequence. The assumption generated by this discovery was thai the beagle intron 6
5' sequence, determined for the first time in this project, was homologous to the G R
intron 6 5' sequence. This assumption would be proven to be correcl ij the A 0
designed around the exon 6flnlron 6 boundary could be shown to induce exon
skipping in GRMD dogs.
7 .1.6

GRMD AO-Induced Exon Skipping: Future Directions
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There are only two previous report ol successful in vitro AO-induced ex on skipping n
the dyslrophin gene, and both of these employed the mdx mouse dystrophin gene
(Dunckley el al. 1995; Wilton el al. 1999). But the success of these authors at using
AOs to induce in

vitro exon slipping raises confidence that, with sufficient trials,

experimental conditions for in vitro AO-induced GR dystrophin exon skipping will be
optimised.

The AOs designed from the work reported here will eventually be

employed to induce the precise splicing of exons 6 and 8, to remove the mutation
causing GRMD and, hopefully, produce sufficient quantities of functional dystrophin to
encourage in vivo GRMD trials.

New difficulties will then confront in vivo genetic therapy mediated by AO technology.

7.2

Human Gene Expression, AOs and Genetic Therapy

In its application to genetic therapy, AO intervention attempts to alter, in a precise way,
an enormously complex system. That

~

can be done for mdx dystrophin in vitro has

been demonstrated (Dunckley et al. 1998; Wilton et al. 1999).
vitro GRMD dystrophin is very likely.

That~

will be done i1

To achieve such success in vivo requires

consideration of two further factors.

7.2.1

Redefining Genes

Traditionally, genes were considered as entities that controlled specific activities in cells
or organisms.

More recently, genes have been redefined as sequences of

nucleotides, each coding for one specific polypeptide product. This definition is now
inadequate and is under review. The vast majority of genes in humans are transcribed
individually and the term 'gene' and transcription unit are interchangeable. But a variety

tot

I

of alternative processing events are now known to occur commonly in all complex

eukaryotes where gene expression has been studied (Strachan & Read, t 996, p p.
t 60- t 63).

The net result of alternative processing events, is that individual

transcription units encode several products.

Alternative processing

can

occur at

transcriptional or post-transcriptional levels of human gene regulation. It is at this point
that the tenm 'gene' and ijs meaning becomes blurred.

They can no longer be

described as sequences of nucleotides, each coding for one specific polypeptide
product.

Two alternative processing events seem to be relevant to in vivo A 0

technology and the expression of the dystrophin gene.

Both operate al the

transcriptional level of gene regulation.

First, in the application of AO technology to genetic therapy described here, AOs
were designed to directly interfere with the function of the spliceosome. Improved
understanding of the operation of this complex molecule can only improve the
optimisation of conditions for AO-induced exon skipping.
splice and alternately splice?

How does this molecule

What and how does the spliceosome assist the

production of several products from individual transcription units?

The second alternative processing event that appears to be of significance to genetic
therapy AO, is the use of alternative promoters in some human genes.

These

promoters appear lo be largely cell-specific promoters.

7 .2.1

The Spliceosome

Recent investigation of the spliceosome, the central eukaryolic enzyme complex that
removes inlronic sequences from mRNA precursors, has shown the behaviour and
interactions of its individual proteins to be extremely complex.

Twenty-five

spliceosome proteins were identified by amino acid sequencing and a further 19 from
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expressed sequence tag (EST) databases (Neubauer et at., t998). These authors
also identified 4 novel spliceosome proteins.

In addition, the spliceosome contains

several RNA components, many of its proteins exist in sub-stoichiometric amounts
and complex pattems of post-translational modification occur (Neubauer et al., 1998).
How spliceosome components interact with each other and with other cell
components, will require the evaluation of an enormous number of interactions.

Direct fluorescent microscope evidence for the location of proteins can be obtained
from in vivo expression of green fluorescent protein (GFP) fusions.

This technique

involves the fusion of full-length eDNA to the Aequorea victoria jellyfish gene encoding
GFP.

These constructs were used to transfect host cells where the gene under

investigation is expressed. Naeuber et al. (1998) used this technique to locate their
newly discovered spliceosome protein to the nucleus of Hela cells, strengthening the
case for their status as spliceosome proteins.

Decoding the functional genomics of the spliceosome presents a formidable problem.
The major components have been identified, now the huge number of possible
interactions of functional signoicance must also be identified for the systematic
optimisation of exon skipping AO genetic therapy. For example, decoding the way i1
which upstream and down stream intronic pyrimidine tracts interact with components of
the spliceosome during splicing (Kennedy et al. 1998) may enable highly specific
AOs to be developed to improve the efficiency of axon-skipping.

7.2.3

Alternative Promoters in Dystrophin

At the lranscriptionallevel, human genes have complex cis-acting sequence elements,

which include, response elements, enhancers, silencers and promoters (Strachan &
Read, 1996, pp. 160-163). The presence of alternative promoters in one gene are
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of interest here. We now know that human genes can have several promoiers, a fact
that could complicate the application of in vivo AO technology as a genetic therapy.
Promoters are usually upstream from a gene, frequently within 200 bp of the
transcription start site. They comprise short sequence elements like the TATA box,
the CCAA T box and the GC box that are recognised by tmns-acting transcription
factors. Alternative promoters in a gene are frequently recognised only by cell-specific

transcription factors.

In 1989 Feener et al. reported that the first exon of the human dystrophin tran5eript
was different in brain and muscle. They concluded that dystrophin expression could
be differentially regulated in these tissues by usage of distinct promoters.

By 1993 knowledge of the complexity of DMD alternative promoters led Ahn and
Kunkel (p. 283) to state:
At least five independent promoters specify the
transcription of their respective alternative first exons
in a cell-specific and developmentally controlled
manner.
Three promoters express full-length
dystrophin, while two promoters near the C temninus
express the last domains in a mutually exclusive
manner.
Strachan and Read (1996, p. 166-167) reported that the dystrophin gene has at loast
7 different promoters and, as a consequence of these alternative promoters, produces
7 dystrophin isoforms. Three of the,>e lead to the transcription of the full 78 exons

n

the dystrophin gene, resulting in a 427 kDa (Dp427) full-length dystrophin protein.
These are the cortical, muscle and PUJ1<inje dystrophins. These three promoters use
different first exons and therefore these dystrophin isofomns differ in their N-temninal
amino acid sequence. The other promoters are located immediately before exon 30
(Dp260, retinal dystrophin), exon 45 (Dp140, central nervous system dystrophin),
exon 56 (Dp116, Schwann cell dystrophin), and exon 63 (Dp71, glial cell dystrophin).
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These dystrophin isolorms have at their N-terminal the first exon translated which will
be homologous to the equivalent region in larger dystrophin isoforms.

So, in the

regions that they overlap, all dystrophin isoforms are homologous, unless aftemative
splicing has changed the reading frame.

This means however that each dystrophin

isoform must be in register, each starting at a dystrophin codon, and not within a codon.

When induced exon skipping involves the first exon(s) of a cell type-specific
expression of a gene, genetic therapy AO could run into problems.

Consider the

possibility of skipping, in vivo, exons that included exon 30 of the dystrophin gene to
produce a reduced length, but in-frame, 'functional' dystrophin molecule. Consider that
this exon skipping effectively reduced DMD symptoms to those of BMD. Unless the
exon-skipping AOs could be prevented from entering retinal cells, the production of
the retinal dystrophin might be abolished by the very same exon skipping AOs
delivering genetic therapy to muscle cells. This would happen if exon skipping were
induced in these cells because such skipping would almost certainly remove the allimportant translation inrtiation codon, most probably located in exon 30. The initiation
codon is almost always AUG (rarely AUG, CUG or GUG) and rt is usually the first
AUG encountered by the 408 ribosomal subunit (Strachan & Read, 1996, pp. 2223). AUG is most efficiently recognised as the start codon when it is embedded in the
optimal surrounding sequence GCCA/GCCAUGG where bold indicates the most
crucial determinants of this surrounding sequence. The removal of AUG in rts initiation
sequence would reduce translation to a very low level, determined by the efficiency

with which the remaining AUG codons were recognised as start codons.

The

inevitable low-level production of variously sized in-frame and out-of-frame products
would effectively abolish translation. Whether this would have clinical consequence,
would, of course, depend upon the precise timing and function of the retinal dystrophin
isoform. Developing systems that deliver AOs to specific cell-types would seem to
be a priority for genetic therapy AO intervention.

Alternative promoters have not been identified for the GR gene. This does not mean
that they do not exist. The developing picture of cell-type alternative promoters in the
human dystrophin gene suggest a cautionary approach be adopted for in vivo AOinduced exon skipping GR trials. At the present state of knowledge, AO-induced
exon skipping of exons 6 and 8 in the hurnan dystrophin gene would not be
compromised by

alternative promoters because the seven

known alternative

promoters are well upstream or downstream from these exons.

7.3

Concluding Comments

This thesis aimed to discover intronic sequences flanking exons 6, 8 and 9 in the G R
dystrophin gene. This aim was achieved. It was intended that these sequences be
used by fellow workers to design AOs that might induce exon skipping in G R
myoblast tissue culture. As

neventuated,

this thesis also reported the first attempt at

AO-induced GR dystrophin exon skipping in GR primary myoblast tissue culture. In
effect, this thesis helped to launch in vitro AO genetic therapy for the muscular
dystrophies, and paved the way for in vivo AO genetic therapy trials in GRMD dogs.
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APPENDIX A

DYSTROPHIN EXONIC PRIMERS

All primers designed prior to this project were ordered through Bresatec (now
known as Geneworks, Australia Inc). Primers ordered through Geneworks during
this project are indicated by •.

Primer
Can1F
CanDyssF·
Can5R
Can6F
Can6R
Exon61R'
Can7F
CanDys?R'
ConDys8F
Can80R
Can8R
DysEX9F
PIGDYS9F
ConDys9R
Can 1OF
ConsDys10R
Can100R
DMD Ex52F
DMD Ex52R
DMD Ex53·F
DMD Ex53·R

Primarv/Nested
P
P
P
P
P
N
P
P
P
N

N
P
N
P
P
N
P
P
P
P

SeQuence 5' to 3'
GTGGGAAGATAGAGGACTG
GGAAATCA(CIT)AAACTGACTCTTGG
TATGTCAGTACTTCCAATATTATTCAC
GTCAAAAATGTAATGAAAAATATCAT
CTATGACTATGGATGAGAGCATTCA
CG(NG)ACCCAGCTCAG(NG)AGAATC
GAACATGCATTCAACATTGCC
TTGTGTGGCTGACTGCTGGC
CAACAAGTGAGCATTGAAGCGAT
GATGGCCTTGGCAACATTTCC
CATTAAGATGGACTTCTTATCTGG
CCTAAGCCTGGATTCAAGAG
CACAGTCAGTCTAGCACAGG
CATAAGCAGCCTGTGTG(NT)AGGCAT
CCT GGA CAG TTA TCA AAC AGC
ACATCATT(NT)GAAATCTCCTTG
AATCTCTCCTTGGGCTTGGAG
AATGCAGGATTTGGAACAGAGCCGTCC
TTCGATCCGTAATGATTGTTCTAGCCTC
TTG AAA GAA TTC AGA ATC AGT GGG ATG
CTTGGTTTCTGTGATTTTCTTTTG GATTG

~;an: pnmer spec. 1c tor (.;antne cUNA sequence; ~;on: Gonsensus ot eDNA
sequences bwtween species ie human, dog and mouse. DMD: primer specilic
for the human eDNA sequence

VECTOR PRIMERS

Primer

M13 universal~ F
M13 universal- A
T7 promotor
T3 promotor

Seauence 5' to 3'

CGCCAGGGTTTTCCCAGTCACGAC
AGCGGATTTCAATTTCACACAGGA
AATTAACCCTCACTAAAGGG
TAATACGACTCACTATAGGG
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MATERIALS

List of reagents and chemicals

Supplier

ReagenUchemical

Ampicillin

Amresco®

ABI Prism Big Dye Terminator cycle

Applied Biosystems

sequencing Ready reaction kit
Bacto®agar

Dileo laboratories, USA

Bacto®tryptome

Dileo laboratories, USA

BactoCyeast extract

Dileo laboratories, USA

BamH I

Promega, USA

Bovine serum albumin (BSA)

Promega, USA

Bromo phenol blue -xylene cynol

Sigma®, USA

Chloroform

Sigma®, USA

DNA Isolation Kit for Cells and Tissues

Roche Diagnostics, Australia

DMW- 1OOM molecular weight marker

Geneworks, Australia

EDTA

Sigma®, USA

Elongase enzyme mix

GibcoBRL, USA

Ethanol

AnalaR®, Australia

Ethidium Bromide

Sigma®, USA

Glacial acetic acid

AnalaR®, Australia

Gelatin

Sigma®, USA

Glycerol

Sigma®, USA
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Isopropanol

AnalaRr~.

Kanamycin

Amresco(f9

LipofectAMINE® reagent

GibcoBRL, USA

Lipofectin® reagent

GibcoBRL, USA

Low melt analytical grade agarose

Promega, USA

Magnesium sulfate

Aldrich, USA

Maltose

Sigma®, USA

Molecular biology grade agarose

Scientifix Scientific supplies

Platinum Taq DNA Polymerase

GibcoBRL

Paraffin oil

Sigma®, USA

Platinum Taq DNA polymerase

GibcoBRL, USA

PUC DNA marker

Geneworks, Australia

OPT!-MEM® reagent

GibcoBRL, USA

Qiaquick Purification Kit

QIAGEN

RNAase A

Tel Test, USA

RNAzol B

Tel Test, USA

Sau3A

Promega, USA

Shrimp alkaline phosphatase (SAP)

USB, USA

Sodium acetate

AnalaR®, Australia

Sodium chloride

AJAX chemicals

Sodium Hydrogen Carbonate

AJAX chemicals

SPP-1/EcoRI molecular weight marker

Geneworks, Australia

T. th DNA polymerase

Biotech International, Australia

T41igase

Life technologies

Australia

Promega, USA
Titan Expand RT-PCR

GibcoBRL, USA
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Tri-Hydrocloric acid

SigmaC'<l, USA

Tris base

Sigma®, USA

Xba1

Promega, USA
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APPENDIX C: Stock Reagents

All stock solutions were made accor<J'1ng to Sambrook eta/. (1989) unless denoted by

•

POLYMERASE CHAIN REACTION
Deoxynucleotide Buffer (5.2

100

and 5.1

50

)

A stock of deoxynucfeotide buffer, containing deoxy- adenine, thymine, guanine and
cytosine was prepared and stored in 100 1.11 aliquots at -20°C.

5.2

100

PCR Buffer

Amount (I-ll)

1Ox Reaction buffer

500

1M MgCI2

10

SmM dNTPs

100

water

390

5.1 50 PCR Buffer

Amount

(~I)

1Ox Reaction buffer

500

25Mm MgCI2

200

SmM dNTPs

50

water

250
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AGAROSE GEL ELECTROPHORESIS

Glycerol loading buffer

A stock ol6x glycerol loading buffer was prepared and stored in 1 ml aliquots at 4°C.

0.2S%

Bromophenol blue

0.2S%

Xylene cyanol

30%

Glycerol in water

TAE electrophoresis buffer {SOX)

A 1 litre stock SOx TAE was prepared by combining 232 g ol Tris base, S7.1 ml Glacial
acetic acid and 100 ml O.S M EDTA (pH 8.0) and marking up to 1 L with millipore H20.
The pH was then adjusted to 8.2 with glacial acetic acid. The working concer.tration ol
1x TAE was obtained by diluting 80 ml ol SOx TAE to a linal volume of 4 L in millipore
H20. Both the stock and 1x TAE solutions were stored at room temperature.

Ethidium Bromide

A O.S f!g/ml working solution of ethidium bromide was prepared by adding 100 ~I of
10mg/ml slack to a final volume of 2 Lin millipore H20. The working solution was stored
in a light resistant bottle at room temperature. The stock solution was stored at 4°C.
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BACTERIAL MEDIA AND REQUIRED SOLUTIONS

LB Media

1

l~re

stock solutions of LB Medium (Luria-Bertani Medium) were prepared. The pH

was adjusted to 7.5 with 5N NaOH and the media was autoclaved on liquid cycle at 15
lbs/sq. inch for 20 minutes.

I

Component
Bacto-trytone

Amount

10g

Bacto·yeast

Sg

NaCI
Agar
(for aaar ofates onfvl

10g
15g

Concentration
1%
0.5%
1%
1.5%

0.7% Top Agar

To 1 litre of LB medium 7 g of agarose was added. The solution was then sterilized by
autoclaving on liquid cycle at 15 lbs/sq. nell for 20 minutes.

Once autoclaved, the

solution was swirled gently to distribute the melted agarose evenly throughout the
solution.

Antibiotics

Alt antibiotics were dissolved in H20 and sterilized by filtration through a 0.22 micron fi~er
and stored as 1 ml aliquots at -20°C.
Antibiotic

Stock concentration

Ampilicillin
Kanamyclin

SOmg/ml
10mg/ml

Working concentration
20mg/m
10mg/ml
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0.5M Ethylenediamine tetra-acetic acid (EDTA) (pH 8.0)

18.6 g of EDTA was added to 80 ml of millipore H2 0. The solution was then mixed
vigorously by a magnetic stirrer. The pH was adjusted to 8.0 with NaOH pellets. The
solution was then autoclaved on liquid cycle at 15·1bs/sq. inch for 20 minutes.

1M Magnesium Sulfate (MgSO,)

74 g MgSO, was dissolved in 300 ml of H20. The solution was then autoclaved on
liquid cycle at 151 bs/sq. inch for 20 minutes.

20% Maltose

20 g of maltose was dissolved in 80 ml of millipore H2 0. The solution sterilised by
fittration through a 0.22-micron filter (Nalgene).

The solution was stored at room

temperature.

SM buffer

1 litre of SM buller was prepared by combining the following 5.8 g of sodium chloride.
2.0 g of magnesium sulfate, 50 ml of 1M Tri·Hydrocloric acid (pH 7.5), 5 ml of 2% (w/v)
gelatin and adding millipore H20 to a final volume of 1 lrtre. The solution was then
autoclaved on liquid cycle and store at room temperature.
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VECTOR DNA EXTRACTIONS

TEG swelling Buffer

25 mM Tris pH 8.0
50 mM EDTA
50 mM Glucose
made to 1 litre with ddH,O

LiCL

106 9 LiCI
5.24 9 MOPS
pH to 8.0 made to 1 lilre with ddH,O

3 M KOAc High salt Neutralisation Buffer

124.9 9 KOAc
25 ml lonnie acid
made to 1 litre wilh ddH,O
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DNA SEQUENCING

3M Sodium acetate

A 3M sodium acetate working solution was prepared by dissolving 40.8g of sodium
acetate per 1OOml of sterile millipore H20. The pH was adjusted to 5.2 by adding
glacial acetic acid. The solution was stored at room temperature.

75% Ethanol

Absolute ethanol was diluted i1 sterile H2 0 to make a 75% (v/v) working solution of
ethanol. The solution was stored at room temperature.
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